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Steroidogenic Factor 1 (SF1) and DAX1 are nuclear receptors that play an 
integral role in the adrenal cortex.  SF1 is a transcription factor that regulates expression 
of myriad genes, including those involved in steroidogenesis, production of various 
endocrine hormones, and development of the adrenals and gonads.  DAX1 is an orphan 
nuclear receptor that inhibits SF1 and, when mutated, is responsible for X-linked Adrenal 
Hypoplasia Congenita (AHC).  In the adrenal cortex, adrenocorticotropic hormone 
(ACTH) activates SF1-mediated transcription of the genes involved in cholesterol 
transport and steroid production.  However, SF1 is also implicated in adrenal 
proliferation and differentiation; therefore, it is likely that several different signaling 
pathways regulate SF1-dependent transcription by altering cofactor availability or by 
feedback mechanisms that modulate signaling molecules that impinge on SF1 
transactivation.  This thesis describes three genomic targets of SF1 that provide feedback 
upon and affect subsequent SF1 transcriptional activity.  First, I describe the 
identification of Edg5, the sphingosine 1-phosphate receptor, as a target of SF1 using 
chromatin immunoprecipitation-chip microarray (ChIP-chip).  Activation of Edg5 may 
alter levels of intracellular sphingosine 1-phosphate, a ligand of SF1 that activates 
steroidogenesis and stimulates release of adrenal hormones.  I also describe association of 
SF1 on the adenylyl cyclase 4 (Adcy4) promoter.  Though usually an activator, SF1 
represses transcription of Adcy4, which may alter cAMP-dependent activation of SF1.  
x 
 
Finally, I describe an interaction between SF1 and GR to activate expression of Dax1, 
which is abrogated by ACTH.  In all three cases, the genomic target of SF1 encodes a 
factor that can modulate SF1-dependent transcription.  While loss of DAX1 in humans 
results in AHC, Dax1 deficient-mice have a mild adrenal phenotype.  To reconcile these 
disparate phenotypes, I analyzed Dax1-deficient mice across their lifespan.  Young Dax1-
deficent mice have increased steroidogenic capacity, expression of steroidogenic 
enzymes, and proliferation.  However, after 60 weeks all three measures are dramatically 
reduced, suggesting that loss of Dax1 may result in premature differentiation resulting in 
ultimate exhaustion of the adrenal cortex, which has implications for AHC.  Overall, this 
dissertation contributes to the understanding of both SF1-dependent gene regulation and 





CHAPTER 1: INTRODUCTION 
 Nearly three hundred years after the first mention of adrenals in an anatomy text, 
Thomas Addison made the first substantial observations regarding the function of this 
obscure organ, to which he referred as “supra-renal capsules” (1).  In 1855, he presented 
ten clinical cases from patients suffering with what would become Addison‟s Disease, 
whose condition he described as such: 
The leading and characteristic features of the morbid state to which I 
would direct attention, are, anæmia, general languor and debility, 
remarkable feebleness of the heart’s action, irritability of the stomach, 
and a peculiar change of colour in the skin, occurring in connexion with a 
diseased condition of the “supra-renal capsules.” 
Prior to his work, the importance of these organs was a subject of great debate.  The first 
report of a gland superior to the kidney by Bartolomeo Eustachius directly contradicted 
the conventional wisdom of the day that adrenals were nonfunctional tissues, not to 
mention a seminal anatomy volume by Andreas Vesalius, which completely lacked any 
mention of such a gland.  At the time, these structures were believed to be a congenital 
outgrowth of the kidney or simply vestigial organs, and their function remained 
enigmatic for many years.  In fact, a mere ten years before Addison‟s publication, the 
adrenal was declared to be a non-secreting gland (2). 
Addison‟s work ignited study of this obscure gland, which culminated in the 
awarding of the 1950 Nobel Prize in Physiology or Medicine to Edward Kendall, Tadeus 
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Reichstein, and Phillip Hench “for their discoveries relating to the hormones of the 
adrenal cortex, their structure and biological effects” (3).  Amazingly, a mere five years 
later, thousands of patients could attribute a prolonged life to adrenal hormone 
replacement therapy (4). 
It is now understood that, just as he suspected, Addison‟s patients were suffering 
from primary adrenal failure, which manifests with hyponatremia, hyperkalemia, and 
acidosis.  If left untreated, death results from hypoglycemia and shock.  All of these 
symptoms are a result of insufficient production of the adrenal hormones aldosterone and 
cortisol.  Rather than being the build-up of toxic substances within the blood, the darker 
skin complexion is a result of excess circulating ACTH, which occurs when the 
endocrine axis in which the adrenal resides is disrupted.  While adrenal function and the 
etiologies of adrenal-specific diseases are quite well understood today, current endeavors 
now focus our understanding of this organ at the molecular level.  These data will provide 
critical answers to questions regarding the contributions of specific proteins to 
adrenocortical development, as well as leading to therapies for adrenal-specific 
conditions.  This type of intimate knowledge will also lead to the ability to understand 
how cancers form in the adrenal, which will ultimately allow for a more targeted 
approach for their treatment. 
Adrenal Development and Function 
 The adrenal glands reside superior to the kidneys and are responsible for 
coordinating the mammalian stress response.  The adrenal consists of two 
developmentally distinct organs; the medulla and the cortex.  The adrenal medulla is a 
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neuroendocrine gland that produces catecholamine in the classic „fight or flight‟ 
immediate stress response.  The adrenal cortex regulates the long-term stress response by 
modulating salt, pH, and glucose homeostasis.  This is accomplished mainly through the 
hypothalamic-pituitary-adrenal (HPA) axis, of which the adrenal is the terminal organ.  A 
wide variety of signals, or stressors, result in release of corticotropin releasing hormone 
(CRH) and arginine vasopressin (AVP) from the hypopthalamus.  CRH and AVP travel 
through the hypothalamic-pituitary portal vessels to the anterior pituitary where they 
stimulate corticotropes in the anterior pituitary to release adrenocorticotropic hormone 
(ACTH), which is the cleavage product of pro-opiomelanocortin (POMC), into the 
systemic blood.  ACTH is released from the anterior pituitary and travels through the 
bloodstream to the adrenal where it is bound by melanocortin 2 receptors (MC2R).  
Signaling downstream of MC2R results in immediate release of glucocorticoids, cortisol 
(in primates) or corticosterone (in rodents), which then travel through the blood to exert 
their effects throughout the body.  Glucocorticoids are bound by the Glucocorticoid 
Receptor (GR), which is nearly ubiquitously expressed and has diverse effects, such as 
immune suppression and modulation of glucose homeostasis.  Glucocorticoids also 
provide negative feedback at the hypothalamus and pituitary to modulate the release of 
ACTH, in a classical endocrine long feedback loop.  
 There are three concentric functional zones of the adult adrenal cortex that are 
defined by their steroid product as well as the hormone required for activation.  (Figure 
1.1)  All of the hormones produced by the adrenal cortex are cholesterol-derived and 
exhibit only subtle differences from each other based on the nature and location of side 
modifications of the main cholesterol backbone.  Enzymes required for steroidogenesis, 
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which include Cytochrome P450 (Cyp450) and cholesterol transport enzymes, are 
uniquely expressed within the zones of the adrenal cortex.  (Figure 1.2)  Enzymes 
commonly expressed in all three zones include steroidogenic acute regulatory protein, 
(StAR), cholesterol side-chain cleavage enzyme (SCC), 3-hydroxysteroid 
dehydrogenase (3HSD), and steroid 21-hydroxylase (21-OH).  The outer-most zone of 
the cortex, the zona glomerulosa (zG), uniquely expresses the enzyme CYP11B2, which 
converts corticosterone into aldosterone, as well as the angiotensin II receptor, which 
allows these cells to be activated by the renin- angiotensin pathway.  The zona fasciculata 
(zF) expresses the enzyme CYP11B1, which is required for the hydroxylation of 
deoxycortisol into cortisol.  CYP17 is expressed in the fasciculata and zona reticularis 
(zR) and is required for production of cortisol as well as androgens.  Mice do not express 
Cyp17 and, therefore produce neither of these hormones.  The fasciculata and reticularis 
also express MC2R, which enables a response to circulating ACTH (5). 
 While there is a degree of interspecies variability, both functional and 
histological, among various mammalian species, a common developmental pathway is 
mediated by distinct genetic signals (5, 6).  The adrenogonadal primordium (AGP) is first 
formed by proliferation of mesoderm-derived coelomic epithelia of the urogenital ridge 
(7).  Coincident to invasion by primordial germ cells, the AGP divides into the adrenal 
primordia and gonadal primordia (8).  Proliferation of the adrenal primordia results in 
formation of the fetal adrenal gland, which is marked by large eosinophilic cells 
expressing 17-hydroxylase.  Production of dihydorepiandrosterone (DHEA) in the fetal 
adrenal is converted to estradiol in the placenta and is required for the maintenance of 
early pregnancy (9).  At approximately the same time as formation of the capsule from 
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surrounding mesenchymal cells, the definitive zone begins to form.  This definitive zone 
is what eventually develops into the zonated functional adult cortex.  It is not yet clear 
whether the definitive zone arises from precursors within the fetal adrenal or from within 
the surrounding capsule (10).  Also coincident with encapsulation is invagination by 
neural crest cells that eventually form the adrenal medulla following parturition (5). 
 There is a significant amount of tissue remodeling that occurs both before and 
after birth.  During the third trimester, the definitive zone begins to differentiate into the 
zona glomerulosa and zona fasciculata, but the reticularis does not form until the third 
post-natal year.  Approximately three months after birth, the fetal zone regresses, leaving 
a band of fibrous connective tissue surrounding the medulla.  Adrenocortical remodeling 
is complete with the onset of adrenarche, which occurs during puberty and results in 
significantly increased production of sex steroid precursors from the reticularis (5, 9, 11).  
The mature adult cortex maintains organ homeostasis through constant replenishment by 
way of inward centripetal displacement of cells from the periphery of the gland (7, 12). 
 While there are definitely differences between the primate and murine adrenal, the 
developmental patterns share a great deal of similarity.  The mouse adrenal, in a fashion 
similar to the primate adrenal, also develops from an adrenogonadal primordium that 
arises from the urogenital ridge.  The process of invasion by neural crest cells, forming 
the medulla, and encapsulation by mesenchymal cells is also strikingly similar to human 
adrenal development, yet follows a different timetable (5, 9).  A major advantage of 
mouse models is a greater ability to understand adrenal development through genetic loss 
of function studies.  In both species, formation of the adrenogonadal primordium is 
dependent upon expression of the nuclear receptor, Steroidogenic Factor 1 (SF1), which 
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is expressed in the expanding coelomic epithelial cells (6, 13, 14).  The contributions of 
SF1 to adrenal development will be discussed in further detail later in this chapter. 
While the mouse and human adrenal have a great deal of genetic and 
developmental similarity, there are some differences between the species.  The primary 
difference between the species is the lack of formation of a zona reticularis in mice, 
mainly because there is no expression of Cyp17, which is required for production of 
cortisol as well as sex steroids.  As such, the mouse adrenal does not form a traditional 
fetal zone, but does have a fetal structure that expresses steroidogenic factor 1 under a 
fetal-specific enhancer (15).  Additionally, the mouse forms a similar transient structure, 
called the X-zone, which appears at the second post-natal week and regresses at puberty 
in males and during the first pregnancy in females (16-18).  While the relationship 
between the fetal zone and the X-zone has been debated, it seems that the X-zone is a 
remnant of the mouse fetal adrenal (15, 19).  Interestingly, the orphan nuclear receptor, 
DAX1 (Dax1 in mice) seems to be required for regression of the human fetal zone and 
the murine fetal and X-zones (19-21).  Dax1 will be discussed in greater detail later in 
this chapter. 
The adult adrenal cortex is a dynamic organ that continuously repopulates.  
Injection with agents that label dividing cells, BrdU or tritiated thymidine, initially labels 
cells of the outer cortex, with the label progressively moving toward the medulla (12, 22, 
23).  Enucleation studies in rats, in which the inner contents of the adrenal are removed, 
demonstrated regeneration of the adrenal cortex into steroid-secreting zones within 30 
days (24, 25).  Additionally, transplantation of primary bovine adrenal cells that were 
derived from a single clone into adrenalectomized mice resulted in replacement of the 
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host animals‟ adrenal function (26, 27).  The transplanted tissue even begins to form into 
architecture that resembles normal adrenal cortex.  Finally, studies in transgenic mice, in 
which the beta-galactosidase reporter gene was expressed under the control of a steroid 
hydroxylase resulted in variegated expression and chord-like mosaic patches that 
extended throughout the entire cortex (28, 29).  Taken together, all of these data suggest 
that the adrenal cortex is maintained by proliferation of cells at the periphery of the 
cortex followed by displacement of the cells inward toward the medulla. 
Steroidogenic Factor 1 
Steroidogenic Factor 1 (SF1) is a nuclear receptor (NR5A1) (30) that was first 
identified as a factor that bound an AGGTCA motif in the promoter regions of the genes 
encoding steroidogenic enzymes and is critically required for transcription of these genes 
in steroidogenic tissues, namely the adrenal cortex and gonad (31-33).    Members of the 
nuclear receptor superfamily typically display conserved features such as a DNA binding 
domain (DBD), a ligand binding domain (LBD), and two activation domains that are 
either independent (the amino-terminal AF-1) or dependent (the carboxy-terminal AF-2) 
upon a ligand for activation (34).   Nuclear receptors are DNA-dependent transcription 
factors that are often regulated by small lipophilic molecules, such as adrenal or gonadal 
steroids or other hormones, although a number of receptors, for which ligands do not 
exist or have not been identified, are termed, „orphan receptors‟ (35).  Many nuclear 
receptors translocate to the nucleus following ligand binding where they bind to DNA as 
homo- or heterodimers.  However, SF1 is constitutively nuclear (36), contains a typical 
DBD, and binds DNA as a monomer (37).  The amino-terminal region is very short and 
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lacks a typical AF-1 domain. However, SF1 contains a conserved AF-2 that interacts with 
coactivators and is required for transcriptional transactivation (36, 38-40).  (Figure 1.3) 
SF1 in Adrenal Development 
 As would be expected for the master regulator of steroidogenesis, SF1 is 
expressed in all major steroidogenic tissues, namely the three zones of the adrenal cortex, 
testicular Leydig and Sertoli cells, and ovarian, theca and granulosa cells (33, 41-43).  
SF1 is also expressed in the anterior pituitary and ventromedial hypothalamus (42-44).  
SF1 is first expressed in the urogenital ridge during the formation of the AGP (13, 14) 
and expression persists in the organs that are derived from this structure throughout 
adulthood.  Following the initial cloning and isolation of SF1, it was thought that this 
nuclear receptor was only involved in the synthesis of steroid hormones in adrenals and 
gonads.  Therefore, it was somewhat surprising that SF1 was also required for proper 
adrenal and gonadal development (45).  Indeed, mice lacking expression of Sf1 do not 
develop adrenals or gonads, have male-to-female sex reversal with persistent Müllerian 
structures, and die shortly after birth due to adrenal insufficiency (46, 47).  This 
requirement of SF1 suggests the reason complete deletions of the human SF1 gene have 
not been reported.  However, human patients with insufficient SF1 expression,  whether 
by mutations or deletions of one copy, demonstrate XY sex reversal and adrenal 
insufficiency (48, 49).  Reconstitution of such mutations usually result in reduced 
transcriptional transactivation ability of the SF1 protein on relevant steroidogenic target 
gene promoters, indicating that SF1 is necessary for activation of some target genes 
during developmental processes (48). 
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 The developmental role of SF1 is further strengthened by studies involving forced 
expression in SF1-negative cells.  Expression of SF1 in embryonic stems cells resulted in 
induction of cholesterol side-chain cleavage enzyme and cAMP-induced progesterone 
synthesis (50).  Using mouse and human bone marrow mesenchymal cells, SF1 
expression resulted in transformation into cells that expressed most of the required 
enzymes for steroidogenesis and were able to synthesize progesterone, corticosterone, 
cortisol, dihydroepiandrosterone, testosterone, and estradiol in response to ACTH (51, 
52).  Finally, using adipose tissue-derived mesenchymal cells, a similar transformation 
occurred, but with a shift toward production of adrenal hormones, such as corticosterone, 
rather than gonadal hormones, such as testosterone, that was observed in the bone 
marrow-derived mesenchymal cells (53).  Together, these studies show that SF1 is able to 
direct nascent cells toward competent steroid-producing cells. 
 Regulation of SF1 expression is quite complex and relies on tissue-specific cis-
regulatory elements that control expression of SF1 in different tissues.  Using transgenic 
mice, in which β-Galactosidase is expressed under the control of the contiguous Sf1 gene, 
both pituitary and VMH enhancers have been mapped to intron 6 of the Sf1 gene (54, 55).  
Using the same approach, the fetal adrenal enhancer (FAdE) has been mapped to intron 4 
(15).  FAdE expression is induced by a homeodomain complex, Hox-Pbx-Prep1, and 
maintained by that complex along with autoregulation by Sf1 itself.  Interestingly, mice 
lacking the Pbx gene do not develop adrenals, yet do develop gonads in which Sf1 is 
expressed (56), suggesting that there is a different factor and/or enhancer site controlling 
expression of Sf1 in these tissues. FAdE expression does not persist through development 
of the adult adrenal (it disappears with the X-zone), suggesting that there is another adult 
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definitive adrenal enhancer (DAdE).  However, lineage tracing has shown that FAdE-
positive cells do ultimately become adult cortex but the enhancer that maintains Sf1 
expression in the adult cortex has yet to be determined (19).   
SF1-mediated Transcription 
 While many members of the nuclear hormone receptor family are activated by 
direct interaction with their cognate hormone ligand (34), transcriptional activation of 
SF1 by ACTH occurs through intermediate signaling cascades (57).  ACTH binds to the 
transmembrane G protein-coupled receptor, MC2R, which results in activation of 
adenylyl cyclase, subsequent accumulation of cAMP, and activation of protein kinase A 
(PKA) which initiates the initial steps of conversion of cholesterol to pregnenolone in the 
steroidogenic pathway (58).  Additionally, PKA activates enzymes within the adrenal 
cortex, namely phosphorylation of StAR, which transports cholesterol from the outer to 
the inner mitochondrial membrane and is the rate-limiting step of steroidogenesis (57, 59, 
60).  Even though gene expression of many of the enzymes involved in steroidogenesis is 
intimately linked to cAMP signaling and SF1 activity, it is not clear that PKA directly 
phosphorylates SF1 (61).  Rather, it seems cAMP-dependent signaling dephosphorylates 
SF1 and affects recruitment of SF1 to active transcriptional foci as well as its dynamic 
interaction with regulatory factors (62-64). 
 ACTH has also been shown to signal through mitogen-activated protein kinases 
(MAPK) ERK1/2 in addition to PKA (63).  SF1 is phosphorylated by ERK2 on Ser
203
 in 
the hinge region of the protein, which increases cofactor interaction, causes it to adopt an 
active conformation, irrespective of ligand binding, and increases transactivation of 
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reporter constructs (65, 66).  However, in vivo studies have shown that Ser
203
 
phosphorylation is coincident with cyclical interaction of SF1 with target chromatin DNA 
that is abrogated by pharmacological inhibition of either the MAPK or PKA pathway, 
indicating that the cyclical phosphorylation/dephosphorylation pattern is required for 
transcriptional activation (67).  These pathways also coordinate SF1 transactivation of 
Glycoprotein Hormone alpha-Subunit in pituitary gonadotropes (68).  It has recently been 
shown that other factors, such as CDK7 and SUMOylation, can also modify the extent of 
Ser
203
 phosphorylation and affect its basal transcriptional activity (69, 70).  In short, 
several signaling pathways seem to converge to coordinate basal transcriptional activity 
of SF1 that sometime synergizes with cAMP induction. 
 Activity of nuclear receptors is also greatly affected by availability of and 
interaction with cofactors (71).  SF1 has been shown to interact with a number of 
coactivators, such as CBP/p300, GCN5, and all three SRCs.  SF1 also interacts with 
corepressors SMRT and RIP140.  These cofactor interactions are facilitated by 
interaction of the conserved AF-2 domain of SF1 with an LXXLL binding motif found in 
many cofactors (72, 73).  Interaction of SF1 with specific cofactors is often facilitated or 
modified by signaling cascades; cAMP and PKA promote interaction with SRC-1 and 
SRC-3, while inhibiting interaction with SRC-2 (74, 75).  Indeed, mice deficient for Src-
1 have altered HPA stress response, suggesting that certain cofactor interactions are 
preferred over others in certain cellular or genomic contexts (76). 
 SF1 also interacts with other transcription factors in a promoter-specific context.  
Not surprisingly, in light of its cooperative activation with cAMP, SF1 interacts with 
CREB to transactivate cAMP-responsive SF1 target genes (77).  Notably, SF1 also 
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cooperates with β-Catenin to activate transcription of alpha-inhibin as well as the orphan 
nuclear receptor, Dax1 (78, 79).  In addition to transactivating expression of Dax1, SF1 
also interacts with the Dax1 protein, which binds via the same LXXLL motif that enables 
interactions with other coactivators (80).  Due to this similar mode of interaction, Dax1 
acts as a transcription repressor of SF1 by directly competing with coactivators such as 
SRC-1 in addition to its association with corepressors, such as NCoR and Alien (81, 82).  
It is very likely that SF1 interacts with additional transcription factors to cooperatively 
regulate transcription of certain promoters and future studies will be focused on 
identifying the entirety of the SF1 interactome. 
Genominc Targets of SF1 
 Many of the genomic targets genes of SF1 have been identified by using transient 
transfection assays using a limited portion of the promoter or regulatory region of the 
target DNA.  In adrenocortical cells, SF1 increases expression of all the enzymes 
required for steroid hormone biosynthesis, the ACTH receptor, and steroidogenic acute 
regulatory enzyme.  Additionally, SF1 modulates the gene expression of various factors 
that are involved in detoxification of byproducts of steroidgenesis, such as aldose 
reductase-like protein, or cellular acquisition or synthesis of cholesterol, such as 
scavenger receptor B1 and HMG-CoA synthase (83-85).  As would be expected, cells 
with a mutation that impaired SF1 function had dramatically reduced expression of many 
of the genes involved in steroid synthesis, such as MC2R, StAR, and CYP11A (86). 
 SF1 seems to be required to develop and maintain the male phenotype.  Müllerian 
inhibitory substance (MIS), which suppresses formation of Müllerian structures into 
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female internal genitalia, is stimulated by SF1 (87, 88).  SF1 also increases expression of 
insulin-like peptide 3, which is important for descent of testicles and for male germ cell 
survival (89, 90).  Finally, SF1 plays a key role in sex determination by cooperating with 
SRY to activate the SOX9 gene and promote the differentiation of Sertoli cells (91).  It is 
therefore not surprising that males heterozygous for SF1 mutations display various 
degrees of sex reversal. 
 Expression of SF1 in pituitary gonadotropes is responsible for regulating the 
reproductive axis, specifically by regulating the expression of LHβ and FSHβ, as well as 
GnRH receptor (44, 92, 93).  Interestingly, SF1 expression in the VMH seems to play a 
role in appetite control and energy balance by driving expression of such factors as brain-
derived neurotrophic factor (BDNF) and cannabinoid receptor (94, 95). 
 There have been several studies looking at global gene expression in adrenal cell 
lines that provide insight regarding genomic targets of SF1.  In Y1 mouse adrenocortical 
carcinoma cells, ACTH treatment resulted in the expected increased expression of genes 
required for steroid synthesis and metabolism.  Interestingly, though, there was a 
significant downregulation of transcripts involved in DNA replication, cell division and 
RNA processing (96).  This study documented changes in well over 1200 transcripts, 
both up and down, of which only 56% were also regulated by cAMP and only 6% were 
regulated by PKC, suggesting that a significant portion of ACTH signaling occurs 
through other pathways, such as MAPK or Ca
2+
.  Another study compared the effect of 
ACTH stimulation on human adult and fetal primary adrenocortical cells (97).  In these 
primary cells, there were many fewer transcripts activated than what was observed in Y1 
cells, and hardly any were downregulated by ACTH.  Surprisingly, no cell division or 
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DNA replication transcripts were downregulated, as was observed in the Y1 cells, 
suggesting that this phenomenon might be unique to the Y1 cells.  Finally a third study 
performed global expression profiling after overexpressing SF1 in H295 human 
adrenocortical carcinoma cells, which resulted in upregulation of proliferation markers in 
addition to the expected steroidogenic transcripts (98).  This finding was further verified 
by generation of a transgenic mouse that express multiple copies of the Sf1 gene, which 
had many hyperplastic lesions and formed adrenal tumors.  Interestingly, SF1 also seems 
to be overexpressed in some cases of childhood adrenocortical tumors (99).  Together, 
these results suggest that SF1 has a much wider range of genomic targets than simply 
steroidogenic enzymes or components of the HPA or HPG axis, and includes factors that 
are involved in differentiation or proliferation in certain physiological contexts.  
Microarrays on ACTH-treated cells capture changes that are both SF1-independent and 
SF1-dependent.  However, it is somewhat surprising that there are such dramatic 
differences in effect among the different cell types and they may simply be artifacts of 
the phenotype of the particular cells that were used in the studies, or a result of the 
different array platforms used. 
Identification of an SF1 ligand 
 The putative ligand for SF1 has been the subject of debate for a number of years.  
Initially, it was thought that SF1 was an orphan receptor because of its constitutive 
activity when expressed in cells.  Additionally, SF1 binds DNA as a monomer, whereas 
most ligand-activated receptors bind DNA as homo- or heterodimers, and the LBD 
appears to adopt a permanently stabilized conformation (34, 66).  However, the AF2 
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within the LBD is conserved across species, suggesting its requirement for ligand binding 
(36, 39, 40).  Initial reports that SF1 was activated by oxysterols were quickly dismissed 
after it was determined that this activation did not occur in relevant steroidogenic cells 
(100-102).  When crystal structural analysis of bacterial-expressed SF1 was performed by 
several groups, it revealed large phospholipids, phosphatidyl glycerol (PG) and 
phosphatidyl ethanolamine (PE), within the LBD (103-105).  While it was first dismissed 
as an artifact of crystal structure purification, the fact that mutations that inhibit 
phospholipid binding resulted in loss of the ability to recruit coactivators or transactivate 
target promoters was a compelling case for their authenticity. 
 Tandem mass spectrometry of immunoprecipitated SF1 purified from H295 cells 
revealed phosphatidic acid (PA) association with the LBD, with PA able to stimulate 
SF1-dependent transcription of the CYP17 promoter (106).  Interestingly, it was also 
determined that SF1 interacts with diacylglycerol kinase theta (DGK-θ), which is 
involved in production of PA, and cAMP signaling results in production of both DGK-θ 
and PA.  Additionally, sphingosine was observed to bind the LBD and inhibit SF1-
dependent transcription, becoming the first natural SF1 antagonist (106).  Structural 
analysis of SF1 bound to different phospholipids revealed that there is a conformational 
change in the LBD when phosphatidyl choline (PC) or phosphatidyl inositol di- and 
triphosphates (PIP2 and PIP3) are bound compared to bacterial phospholipids, suggesting 
that a dynamic exchange between different phospholipid molecules affects cofactor 
recruitment and, therefore, transcription (107). 
 Perhaps the strongest support for lipid ligands of SF1 stems from the finding that 
ACTH signaling activates sphingosine kinase, which converts sphingosine to sphingosine 
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1-phosphate (S1P).  S1P is secreted from cells and also activates SF1-dependent 
transcription of the CYP17 gene (108).  Interestingly, it was discovered that sphingosine 
1-phosphate can also stimulate the production of cortisol and aldosterone from bovine 
fasciculata and glomerulosa adrenal cells, respectively (109, 110).  These results strongly 
suggest interplay between ACTH signaling and lipid metabolism that is dependent upon  
SF1. 
DAX1 
  DAX1 (Dosage-sensitive sex reversal, Adrenal Hypoplasia Congenita critical 
region on the X chromosome gene 1) was first identified as the gene altered in X-linked 
Adrenal Hypoplasia Congenita (AHC) (20, 111, 112).  The DAX1 gene encodes an 
atypical nuclear hormone receptor (NR0B1), containing a ligand binding domain in its 
carboxy-terminal region, and in place of a traditional DNA binding domain, a 70 amino 
acid glycine-rich repeat motif in its amino-terminal region (112-114).  (Figure 1.3) 
DAX1 Inhibition of Nuclear Receptors 
 Soon after DAX1 was cloned, it was determined that it acts as a transcriptional 
repressor and is able to inhibit steroidogenesis, specifically by binding to hairpin loop 
structures in the StAR promoter (115).  DAX1 contains a transcriptional repressor 
domain within it carboxy-terminus that is often absent in patients with AHC (113, 114).  
The repeat motif within the amino-terminal region contains an LXXLL-related motif, 
similar to many coactivators, that enables DAX1 to compete for binding to other nuclear 
receptors (80).  Most notably, this motif directs DAX1 to interact with SF1 or LRH1 
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(NR5A2), but it is also important for interaction of DAX1 with activated estrogen 
receptors (ERα and ERβ), androgen receptor (AR), and glucocorticoid receptor (GR) 
(116-118).  Unlike coactivators, DAX1 associates with factors that repress transcription, 
such NCoR and Alien (81, 82).  In vivo evidence for repression ability of DAX1 is 




 mouse that rescues the adrenal 
haploinsufficiency observed in the Sf1
+/-
 mice.  Specifically, adrenal steroidogenesis is 
returned to wild-type levels in the compound knockout (119).  The Dax1-deficient mouse 
will be discussed in greater detail below. 
DAX1 in Embryogenesis and Cancer 
 In light of its role in inhibiting transcription, mainly in steroidogenic tissues, it 
was surprising to find that Dax1 is highly expressed in mouse embryonic stem (ES) cells 
(120).  While initially it was thought to be an artifact, the importance of Dax1 in mouse 
ES cells was strengthened by the knock-down experiments demonstrating differentiation 
induced by loss of Dax1 (121).  Additionally, Dax1 has been placed within the protein 
interaction network of transcription factors required to maintain pluripotency in ES cells 
(122, 123).  Similar to its role in steroidogenic cells, Dax1 acts as a transcriptional 
repressor in ES cells as myriad differentiation and proliferation genes are expressed early 
after Dax1 expression is knocked down (124).  However, it is not entirely clear if DAX1 
plays a role in human embryogenesis given that its expression is very low in human ES 
cells (125). 
 There is an inverse correlation between DAX1 expression and steroid production 
in adrenocortical adenomas, while its expression in adrenocortical carcinomas is highly 
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variable (126, 127).  Given that SF1 expression seems to induce proliferation of 
adrenocortical cells and is overexpressed in childhood adrenocortical tumors, it is not 
unexpected that DAX1 would be expressed at low levels in these same tumors (98, 99).  
Studies have demonstrated that DAX1 expression is correlated with various aspects of 
tumorigenesis in ovarian and breast cancer, yet DAX1 expression is inversely correlated 
with endometrial and prostate cancer progression (128-131).  However, DAX1 plays a 
significant role in non-endocrine cancers as well.  DAX1 is enriched in the tumorigenic 
side-population of the A549 lung cancer cell line (132).  Interestingly, when DAX1 
expression was knocked down in these cells, there was decreased invasion ability in 
Matrigel, colony formation, and xenograft growth (133). 
Dax1-deficient Mouse Model 
 A mouse model was generated in which exon 2 of the Dax1 gene was floxed (21).  
This portion of the gene was then deleted by crossing to a line that expressed cre 
recombinase under the control of a cytolomegalovirus promoter, resulting in germline 
transmission of the deleted allele.  These mice appear to have a mild adrenal phenotype, 
in which the x-zone persists.  However, they display a much more dramatic testicular 
dysgenesis, in which there is progressive degeneration of the germinal epithelium and 
failure of the spermatic chords to develop properly (21, 134).  They do not show signs of 
hypogonadotropism, yet are infertile because of Leydig cell hyperplasia and decreased 
spermatogenesis due, in part, to overexpression of Cyp19 (aromatase), which converts 
testosterone to estradiol and is normally inhibited by Dax1 and results in elevated levels 
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of estradiol.  Interestingly, treatment with the selective estrogen receptor modulator, 
tamoxifen, restores partial fertility (135). 
 The phenotype of Dax1-deficient mice becomes more apparent when viewed in 
the context of Sf1 haploinsufficiency, which results in a blunted response to different 
types of stress (136).  Consistent with its role as a repressor of Sf1, Dax1-deficiency was 
able to increase the acute stress response of Sf1
+/-
 mice to levels similar to wild-type mice 
(119).  This seems to indicate that the primary role of Dax1 in the adrenal is repression of 
Sf1 specifically.  Interestingly, this study also demonstrated that Dax
-/Y
 adrenals are 
hypersteroidogenic and have significantly elevated ACTH sensitivity compared to wild-
type mice (119).  In testes, however, Dax1 seems to work cooperatively with Sf1 to 
promote development of a testicular phenotype (137).  Indeed, on some genetic 
backgrounds, Dax
-/Y
 display gonadal sex reversal due to insufficient expression of Sox9 
(138, 139). 
Adrenal Hypoplasia Congenita 
 Patients diagnosed with AHC present with adrenocortical failure, secondary to a 
hypoplastic/aplastic gland manifesting with symptoms of cortisol and aldosterone 
deficiency, such as hyperpigmentation, salt-wasting crisis with hyponatremia, 
hyperkalemia and hypoglycemia (140, 141).  An appropriate regimen of steroid hormone 
supplements is prescribed, after the initial adrenal crisis is brought under control, for such 
patients and their hormone levels are faithfully monitored.  There are two forms of AHC: 
miniature adult and cytomegalic.  The miniature adult form of AHC is characterized by 
adrenals having a small amount of cortical tissue, comprised of normal adult cortex with 
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normal structure and organization, with little or no fetal cortex.  This form of AHC is 
sporadic or autosomal recessive and most often associated with defects in the central 
nervous system or pituitary (142).  The cytomegalic form of AHC is characterized by 
adrenals with an absent, or nearly absent, adult cortex.  However, the remaining cells are 
large, cytoplasmic, and eosinophilic with disorganized structure (143-145).  (Figure 1.4)  
This X-linked, recessive form of AHC has been linked to mutations or deletions of the 
DAX1 gene.   
X-linked AHC has a bimodal age of onset.  In approximately 60% of individuals, 
X-linked AHC manifests within the first few weeks of life with the remaining 40% of the 
patients diagnosed in childhood (typically between ages 1 and 10) (140).  There is 
considerable variability in the DAX1 mutations found in AHC patients with no single 
event being predominant.  Nonsense and frameshift mutation occur very evenly along the 
entire gene, while missense mutations cluster at the carboxy-terminus in the LBD (140, 
146, 147).  This mutation analysis suggests that the repressor function of DAX1, which is 
located at the carboxy-terminus, is missing or nonfunctional in individuals with AHC.  
Functional analysis of DAX1 mutations reveals that the capability to transcriptionally 
repress SF1 is greatly reduced (140).  Interestingly, there does not appear to be a 
genotype/phenotype correlation, as siblings with the same genetic mutation can manifest 
at ages different by many years (148, 149).  Individuals with X-linked AHC often have 
hypogonadotropic hypogonadism, which becomes evident upon delayed or abnormal 
puberty (150). 
There are case reports that demonstrate rare instances of variant presentations of 
X-linked AHC associated with DAX1 changes.  Several reports have noted cases of early 
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puberty in young children, evidenced by penile and/or testicular enlargement, which may 
be dependent upon excess circulating ACTH (151, 152).  There have been several cases 
where DAX1 mutations manifest in a phenotype in females.  In the first case study of a 
kindred of affected individuals, all of the carrier females had delayed puberty, but had 
normally functioning adrenals (153).  Another case reported AHC in a female infant due 
to skewed X inactivation (154).  Finally, a third case reported a non-symptomatic male 
having a common DAX1 mutation with his daughter who had mild AHC (155).  In this 
case the mild phenotype was attributed to the mutation causing only a slight defect in the 
ability of DAX1 to repress SF1 transactivation. 
A variable phenotype of X-linked AHC that is somewhat more common, but still 
quite rare, is late onset AHC.   In such cases, adult men are diagnosed with adrenal 
insufficiency and, subsequently found to have mutations in DAX1 that result in a mild 
defect (156-158).  Often, these patients initially present with hypogonadotropic 
hypogonadism and suffer an adrenal crisis during times of extreme crisis or physical 
illness. 
Variability of AHC phenotypes provides an interesting avenue of pursuit toward 
elucidating a possible role of DAX1 in progression to adrenal failure.  One interesting 
observation stems from presymptomatic diagnosis of AHC.  In these cases, usually 
brothers of affected individuals, some adrenal hormones are elevated above normal levels 
prior to progression to adrenal insufficiency (149, 159).  The siblings have the same 
genetic mutation, yet their age of diagnosis is different by several years.  In one particular 
instance, the sibling of an infant patient had cortisol elevated above the normal levels, 
then manifested with AHC when he was eight years old, with corresponding cortisol 
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levels below the normal range (149).  Additionally, some children demonstrate early 
puberty, meaning that they have elevated levels of sex steroids (151, 152).  Taken 
together, these phenotypes suggest that, as would be expected, loss of DAX1 results in a 
hyperfunctional adrenal cortex, but only for a brief period. 
Summary 
SF1 and DAX1 are nuclear receptors that play an integral role in development and 
function of the adrenal cortex.  SF1 is a transcription factor that strongly activates 
expression of the genes encoding several of the cholesterol transporters and P450 
enzymes required for the conversion of cholesterol into the steroid hormones of the 
adrenal cortex.  Additionally, SF1 regulates the basal expression of several genes, 
including genes involved in steroidogenesis, endocrine signaling, and growth and 
development.  The tissue and temporal specificity of several of these genes demonstrates 
the subtlety with which SF1-dependent transcription is regulated.  It is likely that several 
different signaling pathways regulate SF1-dependent transcription by altering cofactor 
availability or by modulating signaling molecules that impinge on SF1 transactivation.  
These studies describe the regulation by SF1 of several factors that are involved in SF1-
dependent transcription.  In chapter 2, I describe the results of a chromatin 
immunoprecipitation-chip microarray, in which genomic fragments of SF1 
immunoprecipitate were analyzed on a promoter microarray.  Promoter regions of a large 
number of genes were enriched.  Of particular interest were those involved in 
sphingolipid signaling and metabolism, which would constitute a novel genomic target of 
SF1-dependent transcription.  I also describe an association of SF1 on the Adcy4 
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promoter.  While in most cases SF1 acts as an activator, on the Adcy4 promoter, SF1 acts 
to repress transcription of Adcy4.  Finally, I describe an interaction between SF1 and GR 
to activate expression of the gene encoding Dax1.  In all three cases, the genomic target 
of SF1 encodes a factor that can modulate SF1-dependent transcription.  This suggests 
the existence of several mechanisms by which SF1-dependent transcription is uniquely 
modulated.  In chapter 3, I describe evidence that Dax1-deficient mice develop adrenal 
failure.  While mutations of DAX1 result in Adrenal Hypoplasia Congenita in humans, 
the Dax1-deficient mouse has a mild adrenal phenotype.  These results potentially 
reconcile the disparity of the phenotypes between the two species.  This dissertation 
contributes to the understanding of both SF1-dependent gene regulation and the 




Figure 1.1 Gross histology of the human adrenal. 





Figure 1.2 Adrenal steroidogenesis pathway. 
The process by which cholesterol is converted into adrenal steroid hormones is specific 
for each zone of the cortex.  All of the enzymes represented on this diagram are regulated 
by SF1.  Portions of this pathway are commonly shared between humans and mice.  
However mice do not express CYP17, which means that only corticosterone is produced 
in the zF and they do not have a zR.  DHEA and Androstenedione are converted to 







Figure 1.3 Diagram of nuclear receptors SF1 and DAX1. 
SF1 shares many of the features of a canonical nuclear receptor, except for an AF1.  
DAX1 has a repeat motif at the amino-terminus that also contains LXXLL motifs that 
allow for interaction with other nuclear receptors.  DAX1 also has a repression domain 






Figure 1.4 Cytomegalic cells in an adrenal from an AHC patient. 
Patients with X-linked AHC often have large cytomegalic cells that are eosinophilic.  
Very few normal cortical cells remain.  Image adapted from Lack, EE Pathology of the 
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CHAPTER 2: IDENTIFICATION OF NOVEL SF1 TARGETS 
 This chapter comprises work on several projects with the common theme of 
identification or characterization of SF1 target genes.  Figure 2.4 comprises a portion of a 
manuscript that was published in collaboration with Dr. Bernard Schimmer 
(Endocrinology 149(7):3668-78).  Figures 2.5 – 2.7 comprise a manuscript published in 
Molecular Endocrinology 20(11):2711-23.  Permission was obtained from The Endocrine 
Society to reproduce copyrighted images. 
Introduction 
 Steroidogenic Factor 1 is a DNA-dependent transcription factor that activates the 
gene promoters of steroidogenic enzymes and is required for steroidogenesis (1-3).  SF1 
binds to a DNA response element and recruits a variety of cofactors, which remodel 
DNA or recruit additional factors, resulting in transcriptional activation of these target 
genes (4).  However, the context by which SF1 activates specific promoters and not 
others is not completely understood.  SF1 regulates the basal expression of several genes, 
including genes involved in steroidogenesis, endocrine signaling, and growth and 
development.  Additionally, SF1 activates transcription of genes encoding factors 
involved in steroid hormone synthesis in response to endocrine signals.  Specifically, in 
response to ACTH, SF1 activates MC2R or other zF-specific gene promoters to facilitate 
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the production of cortisol.  However, the fact that steroidogenesis is not required for 
survival until after birth and SF1 is required for development of the adrenals and gonads, 
suggests that SF1 has an additional, developmental role in steroidogenic tissues.  
Therefore, SF1 is likely responsible for activation of a different subset of developmental 
genes in these tissues (5). 
 Previous studies have compared gene expression changes in Y1 mouse 
adrenocortical carcinoma cells when SF1 is stimulated by ACTH or cAMP (6).  As 
expected, many steroid hydroxylases are upregulated in response to these signaling 
cascades.  However, there are large numbers of additional transcripts that are modulated 
as well.  From this study, it appears that ACTH induces transcription of genes essential 
for differentiation, while repressing genes that are associated with proliferation, such as 
DNA replication, cell division, and RNA processing (6).  Similarly, steroidogenic 
enzyme transcripts were highly upregulated in both human fetal and adult primary 
adrenocortical cells after ACTH stimulation (7).  However, proliferation markers were 
not downregulated in these cells.  Gene expression analysis on human H295 
adrenocortical carcinoma cells, in which SF1 was overexpressed, suggests that SF1 plays 
a role in proliferation of adrenocortical tumors (8).  Additionally, mice overexpressing 
Sf1 develop hyperplastic lesions and adrenal tumors.  While these studies may provide 
useful information regarding the SF1 transcriptome, they do not necessarily provide 
evidence of direct activation or repression by SF1, which would require a more direct 
approach. 
 Microarray experiments performed using SF1 overexpressing cells or cells in 
which Sf1 was knocked down, have demonstrated its myriad effects on global gene 
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expression.  Interestingly, all previous studies have shown that SF1 activates transcription 
of target genes.  Yet, gene expression changes in both directions following manipulation 
of SF1 expression, suggesting that it can also behave as a repressor of gene expression in 
some contexts (6).  SF1 does, in fact, repress CYP11B2, which converts corticosterone 
into aldosterone, in the zF (9).  This restricts CYP11B2 expression to the zG, which 
ensures that aldosterone is only secreted from this zone.  However, SF1 has not been 
shown to suppress transcription of any additional genomic targets to date.  But, in light of 
the microarray data, it is feasible that SF1 suppresses additional targets as well. 
 Recent data has shown that SF1interacts with phosphatidic acid (PA) and 
sphingosine, with PA stimulating and sphingosine inhibiting SF1-dependent transcription 
of the CYP17 promoter (10).  PKA signaling results in increased production of PA.  
Structural analysis of SF1 bound to different phospholipids revealed conformational 
changes in the LBD dependent upon the phospholipid species, suggesting that a dynamic 
exchange between different phospholipid molecules affects cofactor recruitment and, 
therefore, transcription (11).  ACTH signaling activates sphingosine kinase, which 
converts sphingosine to sphingosine 1-phosphate (S1P).  S1P is secreted from cells and 
also activates SF1-dependent transcription of the CYP17 gene (12).  SIP can also 
stimulate the production of steroid hormones from bovine fasciculata and glomerulosa 
adrenal cells (13, 14).  These results strongly suggest interplay between ACTH signaling 
and lipid metabolism that is dependent upon SF1.  However no specific link has been 
shown, to date. 
 Adenylyl cyclase is an enzyme that produces cAMP from ATP in response to 
various stimuli and is an important effector of ACTH action (15, 16).  There are nine 
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isoforms that vary in their tissue distribution and by the signaling that mediates their 
action (17).  However, the factors that regulate Adcy expression in the adrenal cortex are 
not well understood.  Adcy4, which is activated by  G protein subunits is expressed in 
the adrenal and is deficient in a mutant clone of the Y1 adrenal cell line (18, 19).  These 
Y1 clones have a defect in SF1 that impairs coactivator association, but maintains DNA 
binding, and have impaired Adcy4 promoter activity, suggesting a regulatory role of SF1 
in Adcy4 expression (20, 21).  
 Cholesterol is converted into bile acids or steroid hormones.  P450 enzymes, 
specific to the liver or adrenal cortex, metabolize this reaction (22).  The nuclear receptor 
Liver Receptor Homolog-1 (LRH-1, NR5A2), activates transcription of these enzymes as 
well as the orphan receptor Short Heterodimer Partner (SHP, NR0B2)(23, 24).  SHP is 
synergistically activated by LRH-1 and Farnesoid X Receptor (FXR), the receptor to 
which bile acids bind, and then inhibits transcription of the enzymes required for bile acid 
synthesis (25).  In addition to the parallels between the two methods by which cholesterol 
is metabolized, there are also striking parallels between the nuclear receptors that are 
involved.  LRH-1 and SF1, as well as SHP and DAX1, share significant homology and 
are closely related within the nuclear receptor superfamily (26, 27).  These similarities 
suggest that a similar feedback loop exists for regulation of glucocorticoid synthesis 
within the adrenal cortex.  
 In this chapter, unique, non-classical interactions involving SF1 are explored.  I 
describe the results of a chromatin immunoprecipitation-chip microarray (ChIP-chip), in 
which genomic fragments of SF1 immunoprecipitate were analyzed on a promoter 
microarray.  Promoter regions of a large number of genes were enriched.  Of particular 
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interest were those involved in sphingolipid signaling and metabolism, which constitutes 
a novel genomic target of SF1-dependent transcription.  I further show that Edg5 may be 
a unique target for SF1 and may interplay with more traditionally known SF1 signaling 
effectors.  I also describe an association of SF1 on the Adcy4 promoter.  While in most 
cases SF1 acts as an activator, on the Adcy4 promoter, SF1 acts to repress transcription 
of Adcy4.  Finally, I describe an interaction between SF1 and GR to activate expression 
of the gene encoding Dax1.  In all three cases, the genomic target of SF1 encodes a factor 
that can modulate SF1-dependent transcription.  This suggests the existence of several 
mechanisms by which SF1-dependent transcription is uniquely affected.  
Materials and Methods 
Chromatin Immunoprecipitation 
 Chromatin Immunoprecipitation (ChIP) was performed as described previously 
(4).  Mouse Y1 adrenocortical carcinoma cells were grown to approximately 90% 
confluence in DMEM supplemented with 7.5% horse serum, 2.5% bovine serum, and 
antibiotics.  Cells were then placed in serum-free DMEM containing 0.05% BSA for 48 h 
and then treated with 2.5 µM α-Amanatin (Sigma) for 2 h.  Cells were washed twice with 
PBS and then incubated in serum free DMEM containing 0.1 µM ACTH or vehicle 
control.  At various time points following treatment, DNA/protein complexes were cross-
linked by incubating the cells in formalin (1% formaldehyde) for 10 min.  The cross-
linking reaction was terminated by incubating with 0.125 µM glycine for 5 min.  Cells 
were washed twice with ice-cold PBS and then collected by scraping into PBS containing 
protease inhibitor cocktail (Sigma).  Crude nuclei were prepared by hypotonic lysis (28).  
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Nuclei were then resuspended in 150 µl of lysis
 
buffer [1% sodium dodecyl sulfate 
(SDS), 10 mM EDTA, 50 mM Tris-HCl
 





and sonicated four times for 10 sec each at 30% power
 
(Fisher Sonic 
Dismembrator, model 300; Fisher Scientific, Hampton,
 
NH) followed by centrifugation at 
4°C for 15 min.  Supernatants
 
were collected and diluted in buffer [0.01% SDS, 1.1% 
Triton
 
X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl (pH 8.1), 167 mM NaCl,
 
1x protease 
inhibitor cocktail] followed by immunoclearing with
 
2 µg sheared salmon sperm DNA 
(Invitrogen), 5 µl
 
preimmune serum, and 50 µl protein A-Agarose [50% slurry
 
in 10 mM 
Tris-HCl (pH 8.1), 1 mM EDTA, 0.5 mg/ml BSA, 0.05%
 
sodium azide, 200 µg/ml 
sheared salmon sperm DNA) for
 
2 h at 4°C.  Immunoprecipitation was performed 
overnight with
 
specific antibodies.  Immune complexes were recovered by addition
 
of 50 
µl protein A-Agarose and incubation at 4°C for
 
an additional hour.  Precipitates were 
washed sequentially for
 
5 min each in buffer TSE I [0.1% SDS, 1%Triton X-100, 2 mM 
EDTA,
 
20 mM Tris-HCl (pH 8.1), 150 mM NaCl], buffer TSE II [0.1%
 
SDS, 1%Triton 
X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 500
 
mM NaCl], buffer III [0.25 M 
LiCl,1% NP-40, 1% deoxycholate,
 
1 mM EDTA, 10 mM Tris-HCl (pH 8.1)], followed by 
two washes
 
in Tris-EDTA.  Immunoprecipitates were extracted two times by agitation in 
fresh
 
1% SDS, 0.1 M NaHCO3.  Eluates were combined and cross-links were reversed by 
heating
 
at 65°C for 4h.  DNA fragments were isolated
 
using a DNA isolation kit 
(Qiagen).  Isolated DNA was used as template in subsequent PCR or qPCR. 
Serial Chromatin Immunoprecipitation 
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ChIP assays were performed as described above through
 
the Tris EDTA (pH 8.0) 
washes.  Complexes were eluted from primary
 
immunoprecipitates by incubation in 10 
mM DTT for 30 min at
 
37°C.  Elutes were diluted 1:50 in re-ChIP buffer [1% Triton
 
X-
100; 2 mM EDTA; 150 mM NaCl; and 20 mM Tris-HCl (pH 8.1)]
 
followed by 
immunoprecipitation with second antibodies (see
 
above) at 4°C overnight.  
Immunocomplexes were recovered, washed,
 
eluted, and analyzed as described above. 
Chromatin Immunoprecipitation on chip microarray (ChIP-chip) 
 For ChIP-chip, chromatin immunoprecipitation was performed as described above 
with an antibody directed against Sf1 using sheared chromatin from Y1 adrenocortical 
cells with and without ACTH treatment.  After final elution, bound DNA fragments were 
amplified using a Whole Genome Amplification Kit (Sigma) (29).  Amplified DNA 
fragments were then labeled, hybridized to a NimbleGen MM8 RefSeq Promoter ChIP-
chip Microarray, which contains over 17,000 2 Kb promoter regions of well-
characterized genes.  This process was performed by NimbleGen.  Signal intensity data 
were obtained from the scanned files using NimbleScan software to generate log2-ratio 
files.  Ratio and peak data were visualized using NibleGen SignalMap software using p ≤ 
0.05 for the confidence level cutoff.  Enriched promoter regions were analyzed using the 
online Transcription Element Search System (TESS, www.cbil.upenn.edu/tess) to 
identify relevant transcription factor binding sites (30).  Functional annotation of genes 
associated with enriched promoter regions was performed using the Database for 




Isolated ChIP DNA was amplified with the appropriate primers spanning response 
elements within the promoter region of target genes using SYBR Green PCR Master Mix 
(Applied Biosystems).  Results were analyzed using the 2
-ΔΔC(T)
 method (32). 
Quantitative RT-PCR 
Total RNA was isolated from tissues using Trizol Reagent (Invitrogen) and 1 µg 
was reverse transcribed using iScript system (BioRad).  The resulting cDNA was diluted 
1:5 and 2 µl was amplified with the appropriate primers using SYBR Green PCR Master 
Mix (Applied Biosystems).  Results were analyzed using the 2
-ΔΔC(T)
 method (32). 
Cell Culture and Primary Adrenal Cell Culture 
 Y1 adrenocortical cells were maintained in DMEM supplemented with 7.5% 
horse serum, 2.5% fetal bovine serum, and antibiotics at 37°C under humidified 
atmosphere of 5% CO2.  Cells were grown on Primaria-coated tissue culture plates.  
Primary cells were derived from
 
B6/SJL F2 mice.  Adrenals were harvested, cleaned, and 
minced
 
by hand.  Single cell suspensions were generated by incubating
 
minced adrenal 
glands in serum-free medium containing 2 mg/ml
 
collagenase, 0.05 mg/ml 
deoxyribonuclease I, and 5 mg/ml BSA
 
at 37°C for 45 min with mechanical disruption 
(pipetting up
 
and down) every 15 min.  Primary adrenal cells were plated on
 
to 
fibronectin-coated plates in Knockout DMEM containing 15%
 
Knockout serum 
replacement (Invitrogen) at a density of 16 adrenals
 
per 6-cm culture plate.  Primary cells 
were allowed to adhere
 




Statistical significance was determined by using an unpaired student‟s t-test to 
compare data from Dax1
-/Y
 mice and wild type mice at each age.  Results were 
considered significant if p < 0.05 and are denoted with an asterisk. 
Results 
Sf1 immunoprecipitation enriches a variety of gene promoters 
 Previous studies have shown wide-ranging effects of ACTH signaling in Y1 cells 
(6). The results of these studies suggest that in addition to activating expression of 
steroidogenic enzymes, ACTH may also induce differentiation of adrenal cells.  In order 
to discover possibly novel Sf1 target genes, ChIP-chip was performed.  Y1 cells were 
treated with 100 nM ACTH or vehicle control and then harvested after 90 minutes as 
described in the methods section.  Nuclear extracts were then immunoprecipitated using 
an antibody directed against Sf1.  Immunoprecipitated DNA was then labeled and 
hybridized to a ChIP-chip promoter array.  Interestingly, there were a variety of gene 
targets enriched, both in the vehicle-treated group and the ACTH-treated group.  Analysis 
of peak data revealed that under basal condition, Sf1 is enriched, or putatively bound, at 
95 different gene promoters.  However, after ACTH stimulation, Sf1 is associated wih 
189 different gene promoters. (Figure 2.1, A)  Interestingly, only 10 gene promoters 
were common to both lists.  Analysis of the promoter regions using TESS, revealed that 
many of the enriched promoter regions contain canonical SF1 response elements.  
 Functional annotation of the enriched gene lists using Database for Annotation, 
Visualization, and Integrated Discovery (DAVID) demonstrated that there is a dramatic 
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difference in the functional categories for the gene promoters to which Sf1 is bound 
under the two conditions.  Under basal conditions, Sf1 is bound to promoters of genes 
encoding cytoskeleton, proliferation, and signaling proteins.  After treatment with ACTH, 
Sf1 is bound to promoters of genes encoding transmembrane, DNA binding and 
differentiation proteins.  Multiple transcriptional regulators are represented on both lists.  
However, because DNA binding in this assay does not infer activation or repression, this 
result is not unexpected.  (Figure 2.1, B)  
 Known ACTH-responsive Sf1 target genes encoding steroidogenic enzymes (such 
as CyB5r4 (33)), were enriched in the ACTH-treated group, albeit not representing the 
most highly enriched sequences.  This may indicate that in the moderately steroidogenic 
Y1 adrenocortical carcinoma cell line, Sf1 participates in functions beyond 
transcriptional regulation of steroidogenic enzymes.  However, promoters of 
steroidogenic enzymes tend to be underrepresented on this particular array.  Consistent 
with recent reports of sphingolipids and phospholipids binding to SF1, there was 
enrichment of genes involved in sphingolipid biology in both the basal and ACTH-treated 
group.  Interestingly, there seemed to be a shift following ACTH treatment, as the genes 
in this category were unique to each group.  While the phosphodiesterase Smpd2 is 
enriched under basal conditions, both the sphingosine receptor Edg5 and the lyase Sgpl1 
are enriched following ACTH treatment.  Notably, two genes specifically enriched in the 
absence of ACTH are Notch2 and Tcf23, which both play major roles in the maintenance 
of progenitor multipotency and inhibition of differentiation.  Interestingly, a number of 
the highly enriched genes in the ACTH-treated group, including Edg5, retinoic acid 
binding protein Crabp1, and the entire reproductive homeobox 4 gene cluster Rhox4 are 
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well-characterized regulators of differentiation of multiple cell lineages (34-36). (Figure 
2.2) 
Edg5 is a target of Sf1 
 Using the TESS database, it was confirmed that Edg5 does, indeed, have an SF1 
response element.  Additionally it corresponded to the area of the promoter that had 
probe enrichment.  To verify that Edg5 is indeed a SF1 target gene, a traditional ChIP 
assay was performed using the same anti-SF1 antibody that was used for the ChIP-chip.  
Immunoprecipitated DNA was amplified using primer sequences designed to flank the 
response element within the promoter region of Edg5.  PCR was also performed using 
primers that correspond to well-know SF1 targets, StAR and Mc2r.  Amplification using 
the proximal Edg5 showed a 4-fold increase in SF1 promoter occupancy compared to 
IgG control.  (Figure 2.3, A) StAR and Mc2r both confirm adequate 
immunoprecipitation by SF1 and they both have between four and 14 fold higher SF1 
occupancy.  Interestingly SF1binding at the Edg5 promoter did not change significantly 
in response to ACTH.  This is at odds with the ChIP-chip data.  The argument that the 
ACTH has lost its potency is dismissed by the fact that occupancy was induced at the 
StAR and Mc2r promoters in response to ACTH stimulation. 
 Because Edg5 was enriched in the ACTH-treated and not the basal ChIP-chip 
array, it would be expected that ACTH stimulation would be accompanied by changes in 
gene expression.  To determine if ACTH can effect change in Edg5 expression, qRT-
PCR was performed.  ACTH induces a modest, but significant, 1.5 fold increase in Edg5 
mRNA expression.  (Figure 2.3, B)  StAR expression was used as a positive control and 
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its expression was also increased, but only by two-fold, which is somewhat less than what 
was expected.   
Sf1 represses activity of the Adenylyl cyclase 4 promoter 
 Recently, it was discovered that Adcy4, which is activated by  G protein 
subunits, is expressed in the adrenal and is deficient in a mutant clone of the Y1 adrenal 
cell line (18, 19).  These Y1 clones have a defect in SF1 that impairs coactivator 
association, but maintains DNA binding, and have impaired Adcy4 promoter activity, 
suggesting a regulatory role of SF1 in Adcy4 expression (20, 21).   In collaboration with 
Dr. Bernard Schimmer at the University of Toronto, the observation was made that both 
SF1 and Sp1 regulatory sequences are present in the 5′ flanking region of the Adcy4 
gene. (Figure 2.4, A)  After electromobility shift and deletion analysis indicated that SF1 
and Sp1 are able to bind the Adcy4 promoter region and SF1 along with Sp1B represses 
its activity, a ChIP assay was performed to determine if SF1 interacts with the Adcy4 
promoter in vivo.  The proximal Adcy4 promoter was amplified from immunoprecipitates 
of anti-SF1 ChIP, but a distal region was not. (Figure 2.4, B)   
 To determine the effect of modulating SF1 expression on the activity of Adcy4, a 
luciferase assay was performed in Y1 cells transfected with an Adcy4 luciferase reporter 
plasmid and a SF1 expression vector.  Overexpression of SF1 resulted in 35% decrease in 
Adcy4 promoter activity, whereas SF1 antisense had no effect.  (Figure 2.4, C)  Finally 
SF1 expression was knocked down in Y1 cells, which resulted in a nearly 3-fold increase 
in Adcy4 mRNA expression, while SF1 and Mc2r expression were both reduced by over 
56 
 
90%.  (Figure 2.4, D)  Together, these data indicate that SF1 acts to repress activity of 
Adcy4 expression in adrenocortical cells.   
SF1 and GR form a complex on the murine Dax1 promoter 
 In the liver, SHP is synergistically activated by LRH-1 and Farnesoid X Receptor 
(FXR), the receptor to which bile acids bind, and then inhibits transcription of the 
enzymes required for bile acid synthesis (25).  Because of the parallels between these 
nuclear receptors and the adrenal nuclear receptor that mediate cholesterol methabolism 
into steroid hormones, the promoter of Dax1 was explored.  It was determined that Dax1 
is synergistically activated by GR and SF1 in response to the glucocorticoid, 
dexamethasone.  (Figure 2.5, A)  Additionally, GR and SF1 interact with each other and 
form a protein complex on the Dax1 promoter.  This complex is formed in the presence 
of dexamethasone and specifically disrupted by ACTH (Figure 2.5, B)   
ACTH treatment results in SF1 clearance from the Dax1 promoter and recruitment to the 
StAR and Mc2r promoters 
 Previous studies have shown that ACTH induces cyclical Sf1 recruitment to 
promoters of steroidogenic genes (4).  Therefore, it was somewhat interesting to find that 
ACTH resulted in clearance of SF1 from the Dax1 promoter.  To confirm that this was a 
specific effect of ACTH, parallel ChIP assays were performed analyzing SF1 
immunoprecipitates on the Dax1, StAR , and Mc2r promoters.  While ACTH treatment 
resulted in clearance from the Dax1promoter, there was 5.5-fold and 8.9-fold increase of 
SF1 occupancy on the Mc2r and StAR promoters, respectively.  (Figure 2.6)   
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Dax1 and StAR are conversely regulated by ACTH and dexamethasone 
 To determine if binding of SF1 and GR to the Dax1 promoter had functional 
consequences, gene expression was measured following dexamethasone and ACTH 
treatment in primary adrenal cells.  Primary adrenocortical cell were treated with vehicle, 
dexamethasone, or dexamethasone plus ACTH for 18 hr.  Quantitative RT-PCR was 
performed on RNA using primers specific to Dax1 and StAR.  Dexamethasone treatment 
alone resulted in 4.5-fold increase in Dax1 expression and a 4.7-fold decrease in StAR 
expression.  Concomitant treatment with dexamethasone and ACTH resulted in 
attenuated Dax1 expression (2.8-fold increase) and a dramatic 10.9-fold increase in StAR 
expression. (Figure 2.7) 
Discussion 
 In this chapter, unique, non-classical interactions involving SF1 were explored.  I 
described the results of a chromatin immunoprecipitation-chip microarray (ChIP-chip), in 
which genomic fragments of SF1 immunoprecipitate were analyzed on a promoter 
microarray.  Promoter regions of a large number of genes were enriched.  Of particular 
interest were those involved in sphingolipid signaling and metabolism, which constitutes 
a novel genomic target of SF1-dependent transcription.  I further showed that Edg5 may 
be a unique target for SF1 and may interplay with more traditionally-known SF1 
signaling effectors.  I also described an association of SF1 on the Adcy4 promoter.  
While in most cases SF1 acts as an activator, on the Adcy4 promoter, SF1 acts to repress 
transcription of Adcy4.  Finally, I described an interaction between SF1 and GR to 
activate expression of the gene encoding Dax1.  In all three cases, the genomic target of 
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SF1 encodes a factor that can modulate SF1-dependent transcription.  This suggests the 
existence of several mechanisms by which SF1-dependent transcription is uniquely 
affected by short intracellular feedback loops.  
Using an unbiased approach for discovery of novel target genes is very useful.  
Previous studies that determined SF1 target sites mainly consisted of analysis of known 
members of the steroidogenesis pathway or factors known to play a role in the HPA or 
HPG axes.  Approaches such as ChIP-chip or the newer technique, ChIPseq (37), offer an 
unbiased method for discovering novel targets of SF1.  Previous gene expression 
analyses suggest that SF1 plays a role in ACTH-mediated differentiation, and that SF1 
can contribute to tumorigenesis in some contexts (6, 8).  The scope would need to be 
expanded outside of the limited cell types in which previous studies were performed.  
There are a limited number of adrenocortical cell lines and it cannot be assured that they 
behave as normal adrenocortical cells would.  Ideally, future ChIP-chip experiments 
would be done on primary adrenocortical cells, similar to the approach used by Xing et al 
(7). 
Sphingosine signaling interacting with SF1 has become an emerging area of 
research.  Most often, however, sphingosine is upstream of SF1 transactivation, yet I 
have shown that it sphingosine signaling may also be downstream.  Further work must be 
done to fully characterize sphingosine metabolism as a bona fide target of SF1.  It is 
interesting to speculate that there may be a feedback mechanism by which SF1 can affect 
intracellular concentrations of sphingosine and sphingosine 1-phosphate to regulate cell- 
and promoter-specific activation or repression.  Future studies would require the use of 
SF1 mutants deficient in their ability to bind different lipid moieties.  Would these 
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mutants transactivate traditional steroidogenic targets?  It is entirely possible that 
interaction with sphingolipids/phospholipids is required for steroidogenesis.  However, it 
is also possible that interaction with sphingolipids may direct SF1 toward a distinct 
subset of genomic targets.  Future studies will focus on revealing this distinction. 
In most cases, SF1 has been shown to activate transcription.  However, there is 
one exception: the repression of CYP11B2 in the zona fasciculata (9).  The identification 
of adenylyl cyclase 4 as a target of SF1 is just the second target that SF1 actively 
represses.  Interestingly, the response element to which SF1 binds to repress Adcy4 is 
nearly identical to the response element it binds to activate traditional steroidogenic target 
genes.  Therefore, the information to activate or repress transcription is not delivered by 
the response element, but must come from surrounding transcription factors acting on the 
same promoter region.  Future studies will focus on identifying genomic sequences 
surrounding the SF1 response element that result in either activation or repression of the 
genomic target. 
Repression of Adcy4 by SF1 might also have an effect on SF1-depenent 
transcriptional activation.  Adcy4 is regulated by  G-protein subunits, so repression of 
this factor would drive cAMP signaling to be influenced more predominantly by other 
signaling pathways. 
DAX1 is yet another SF1 target that feeds back on SF1-dependent transcription.  
In fact this feedback mechanism and the consequences of such appear fairly well defined 
compared to the other two targets reported here.  DAX1 and SF1 share quite an unusual 
relationship.   While they are coincidently expressed in many tissues, they seem to play 
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quite unique roles in adrenal physiology.  The mechanism provided here is sufficient for 
explaining the role of DAX1 in mediating glucocorticoid production and suggests an 
intra-adrenal feedback loop that maintains a balance between d differentiated 
steroidogenically competent cells and undifferentiated progenitor cells.  However, this 
mechanism does little to account for the developmental role that DAX1 has in the adrenal 
cortex.  In fact, the fact that mutations in both SF1 and DAX1 result in adrenal 
hypofunction cannot be explained by a simple repression of SF1-dependent 
steroidogenesis by DAX1.  As DAX1 is a repressor of transcription, there must be other 
critical factors in the developing adrenal that DAX1 represses.  In chapter three, I will go 
into more detail concerning DAX1 in the adrenal cortex. 
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Figure 2.1 Analysis of DNA enrichment following αSF1 immunoprecipitation. 
SF1-immunoprecipitated DNA was hybridized to a NimbleGen MM8 RefSeq promoter 
and results were analyzed using NimbleScan software.  A) Venn diagram showing total 
number of enriched DNA regions in presence or absence of ACTH.  B) Table listing top 
functional categories of genes near enriched DNA regions.  Functional categories were 





Figure 2.2 Visualization of peak data for select enriched DNA regions. 
SF1-immunoprecipitated DNA was hybridized to a NimbleGen MM8 RefSeq promoter 
and peak data was visualized using NimbleScan software.  Each boxed area represents 
the tiled promoter region for a given gene: upper histogram – SF1 binding under basal 
conditions; lower histogram – SF1 binding following ACTH stimulation.  All histograms 




Figure 2.3 Confirmation of Edg5 as SF1 target by ChIP and qRT-PCR. 
A) ChIP assays were performed on Y1 cells using an anti-SF1 antibody after 80 min 10 
nM ACTH stimulation. Immunoprecipitates were analyzed by qPCR using primers 
spanning SF1 RE in the proximal promoters of StAR, Mc2r, and Edg5 genes, as well as 
the distal promoter of Edg5.  Results are plotted as a percentage of the input DNA.  B) 
Quantitative RT-PCR of Edg5 and StAR transcripts following 24 hr 10 nM ACTH 
stimulation.  Results are plotted relative to vehicle-treated, which was set to one.   For 




Figure 2.4 SF1 interacts with Adcy4 promoter and affects its transcription. 
A) Promoter region of Adcy4 contains Sp1 binding sites and SF1 response element.  B)  
ChIP assays were performed on Y1 cells stably expressing myc-HA-SF1 using anti-SF1 
and anti HA antibodies or control IgG.  Immunoprecipitated DNA was amplified using 
primers spanning the SF1 RE (upper gel), or a distal region (lower gel), +2744 
downstream of the transcription start site. C)  Luciferase assays were performed on Y1 
cells transfected with reporter plasmid containing 970 bp (black bars) or 18 bp (white 
bars) of the Adcy4 promoter along with a HIS-tagged SF1 expression vector (SF1+), an 
antisense control (SF1-), or empty vector, pcDNA 3.1.  D) Quantitative RT-PCR of SF1, 
Mc2r, and Adcy4 in Y1 cells following transfection with siRNA targeting SF1.  Results 
are expressed as a percentage of SF1 siRNA (black bars) to control siRNA (white bars).  






Figure 2.5 SF1 and GR synergistically activate Dax1 and form a complex on the 
Dax1 promoter. 
A) Luciferase assays were performed after transfecting JEG3 cells with a Dax1 luciferase 
construct, along with SF1 expression vector, GR expression vector, or both.  Cells were 
treated with increasing amounts of dexamethasone for 12 h. Results were plotted as fold 
over baseline reporter activity. B) Serial ChIP assays were performed on primary adrenal 
cells using anti-GR antibodies followed by anti-SF1 antibodies following 40 min 
treatment with 10 M dexamethasone or 100 nM ACTH, or both.  Immunoprecipitates 
were analyzed by qPCR using primers designed against the proximal and distal Dax1 
promoter.  Results were plotted as fold over baseline.  (*, P ≤ 0.05)  Copyright 2006, The 




Figure 2.6 ACTH shifts SF1 from Dax1 promoter to MC2R and StAR promoters. 
ChIP assays were performed in primary adrenal cells using anti-SF1 and anti-HA 
antibodies after stimulation with 10 nM ACTH for 40 min.  Immunoprecipitates were 
analyzed by qPCR using primers that spanned the SF1 response elements within Dax1, 
Mc2r, and Star proximal promoters.  Results were plotted as fold change over baseline 






Figure 2.7 Dexamethasone and ACTH have reciprocal effects on expression of Dax1 
and StAR. 
Primary mouse adrenocortical cells were treated with 10 uM dexamethasone alone or in 
combination with 100 nM ACTH for 18 hr.  qRT-PCR was performed on isolated mRNA 
using primers specific to Dax1 and StAR.  Results were plotted as fold change over basal 
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CHAPTER 3: DAX1-DEFICIENT MICE DEVELOP ADRENAL FAILURE 
 All work presented in this chapter was performed independently under the 
mentorship of Dr. Gary Hammer.  The data obtained from this work resulted in a first-
author manuscript submitted to Endocrinology. 
Introduction 
 DAX1 (Dosage-sensitive sex reversal, Adrenal Hypoplasia Congenita critical 
region on the X chromosome gene 1) was first identified as the gene altered in X-linked 
Adrenal Hypoplasia Congenita (AHC) (1-3).  Patients diagnosed with AHC present with 
adrenocortical failure, secondary to a hypoplastic/aplastic gland manifesting with 
symptoms of cortisol and aldosterone deficiency, such as hyperpigmentation, salt-wasting 
crisis with hyponatremia, hyperkalemia and hypoglycemia (4, 5).  An appropriate 
regimen of steroid hormone supplements is prescribed for such patients.  While the 
disease typically manifests within the first few weeks of life, there is wide variation in 
age of onset, even when the underlying DAX1 mutation is identical; siblings with the 
same genetic mutation can manifest at ages different by many years (6).  Though X-
linked AHC has been definitively linked to alterations in DAX1, the mechanism by 
which loss of functional DAX1 results in adrenal failure has yet to be delineated. 
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X-linked AHC has a bimodal age of onset.  In approximately 60% of individuals, 
X-linked AHC manifests within the first few weeks of life with the remaining 40% of the 
patients diagnosed in childhood (typically between ages 1 and 10) (4).  There is 
considerable variability in the DAX1 mutations found in AHC patients with no single 
event being predominant.  Nonsense and frameshift mutation occur very evenly along the 
entire gene, while missense mutations cluster at the carboxy-terminus in the LBD (4, 7, 
8).  This mutation analysis suggests that the repressor function of DAX1, which is located 
at the carboxy-terminus, is missing or nonfunctional in individuals with AHC.  
Functional analysis of DAX1 mutations reveals that the capability to transcriptionally 
repress SF1 is greatly reduced (4).  Interestingly, there does not appear to be a 
genotype/phenotype correlation, as siblings with the same genetic mutation can manifest 
at ages different by many years (6, 9).  Individuals with X-linked AHC often have 
hypogonadotropic hypogonadism, which becomes evident upon delayed or abnormal 
puberty (10). 
There are case reports that demonstrate rare instances of variant presentations of 
X-linked AHC associated with DAX1 changes.  Several reports have noted cases of early 
puberty in young children, evidenced by penile and/or testicular enlargement, which may 
be dependent upon excess circulating ACTH (11, 12).  There have been several cases 
where DAX1mutations manifest in a phenotype in females.  In the first case study of a 
kindred of affected individuals, all of the carrier females had delayed puberty, but had 
normally functioning adrenals (13).  Another case reported AHC in a female infant due to 
skewed X inactivation (14).  Finally, a third case reported a non-symptomatic male 
having a common DAX1 mutation with his daughter who had mild AHC (15).  In this 
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case the mild phenotype was attributed to the mutation causing only a slight defect in the 
ability of DAX1 to repress SF1 transactivation.  A phenotype of X-linked AHC that is 
somewhat more common, but still quite rare, is late onset AHC.   In such cases, adult 
men are diagnosed with adrenal insufficiency and, subsequently found to have mutations 
in DAX1 that result in a mild defect (16-18).  Often, these patients initially present with 
hypogonadotropic hypogonadism and suffer an adrenal crisis during times of extreme 
crisis or physical illness. 
Variability of AHC phenotypes provides an interesting avenue of pursuit toward 
elucidating a possible role of DAX1 in progression to adrenal failure.  One interesting 
observation stems from presymptomatic diagnosis of AHC.  In these cases, usually 
brothers of affected individuals, some adrenal hormones are elevated above normal levels 
prior to progression to adrenal insufficiency (9, 19).  The siblings have the same genetic 
mutation, yet their age of diagnosis, is different by several years.  In one particular 
instance, the sibling of an infant patient had cortisol elevated above the normal levels, 
then manifested with AHC when he was three years old, with corresponding cortisol 
levels below the normal range (9).  Additionally, some children demonstrate early 
puberty, meaning that they have elevated levels of sex steroids (11, 12).  Taken together, 
these phenotypes suggest that, as would be expected, loss of DAX1 results in a 
hyperfunctional adrenal cortex, but only for a brief period. 
The DAX1 gene encodes an atypical nuclear hormone receptor (NR0B1), 
containing a ligand binding domain in its carboxy-terminal region, and in place of a 
traditional DNA binding domain, a 70 amino acid repeat motif in its amino-terminal 
region (2, 20, 21).  Murine expression of Dax1 is restricted to tissues involved in 
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steroidogenesis and reproduction, both during development and in the adult (22).  The 
confirmed primary function of Dax1 is as a transcriptional inhibitor of Steroidogenic 
factor 1 (Sf1, Nr5a1), the master regulator of development and function of the HPA and 
HPG axes (23).  Because of its association with corepressors such as NCoR (24) and 
Alien (25), as well as the presence of LXXLL binding motifs (26), Dax1 is believed to 
directly compete at cofactor binding sites of Sf1 (20, 24).  Dax1 has also been shown to 
have additional, less well characterized properties, such as binding to a stem-loop 
structure in the Star promoter (27), acting as a shuttling RNA binding protein (27), and 
inhibiting RNA splicing (28).  None of these ascribed functions of Dax1 adequately 
explain the mechanism by which X-linked AHC develops from loss of DAX1.  However, 
recent proteomics studies have identified Dax1 as a binding partner of ES cell factors 
Oct4 and Nanog, which implicate Dax1 as an important factor within the transcriptional 
network that maintains stem cell pluripotency (29-31).  Indeed, knock down of Dax1 in 
ES cells results in spontaneous differentiation (32, 33).  Additionally, Dax1 also plays a 
role in the etiology of some cancers – its expression correlates with advanced stage in 
ovarian carcinoma and with the stem cell population of lung cancer cells (34, 35).  Taken 
together, these data suggest an important general role for Dax1 in maintaining or 
promoting an undifferentiated state, which suggests a similar function in cells within the 
adult adrenal cortex. 
Consistent with its role as a steroidogenesis inhibitor, Dax1 knockout (Dax1
-/Y
) 
mice, in which exon 2 of the Dax1 gene locus was deleted (36), have enhanced adrenal 
steroidogenesis that rescues adrenal haploinsufficiency of Sf1-deficient mice (37).  These 
mice also have elevated gonadal steroidogenesis, which renders them infertile partly due 
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to elevated expression of p450 aromatase (Cyp19) (38).  However, all of the studies 
performed with Dax1
-/Y
 mice used relatively young animals (less than 10 weeks).  To 
date, steroidogenic analysis of Dax1
-/Y
 mice over the lifespan of the mouse has not been 
performed. 
A current model of Dax1 action implicates it in maintenance of adrenocortical 
progenitor cells, primarily because expression within the adrenal cortex is enriched in the 
subcapsular zone , which is the location of putative adrenocortical progenitor cells (39).  
Indeed, earlier studies have demonstrated that the adrenal cortex is populated from the 
subcapsular zone by inward centripetal displacement (40, 41).   Dax1 expression in the 
adrenal is activated by both Wnt signaling and glucocorticoids, yet inhibited by ACTH, 
placing it within an intra-adrenal feedback loop that regulates steroidogenesis in adrenal 
cells in response to developmental or endocrine signals and plays a critical role in 
differentiation of adrenal progenitors in response to limiting corticosterone levels (42-
44).   In this model, Dax1 deficiency would result in premature progenitor cell 
differentiation (with elevated steroidogenesis) followed by eventual exhaustion.  There is 
clinical support for this model in a handful of case studies in which siblings of X-linked 
AHC patients were monitored before manifesting with clinical adrenal failure (9, 19).  In 
these reports, several patients with DAX1 mutations had elevated adrenal steroid 
hormone production before ultimately failing, suggesting similar consequences for loss of 
Dax1 in mice and humans. 
In an effort to reconcile the disparate phenotypes of mice and humans deficient in 
Dax1, I decided to observe adrenals of Dax1-deficinet mice over an extensive time 
period.  In this study I demonstrate that Dax1-deficient mice have elevated adrenal 
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steroidogenesis – marked by both increased capacity and increased sensitivity – which 
diminishes with age.  Additionally, Dax1-deficient mice have progressively worsening 
adrenocortical dysplasia , which is absent in wild type mice.  Finally, both young and old 
Dax1
-/Y
 mice have markedly different adrenal proliferation rates than their wild type 
counterparts.  This is the first study to demonstrate evidence of adrenal failure in Dax1
-/Y
 
mice, which, taken together, suggests they may be an appropriate model for human AHC.   
Materials and Methods 
Experimental Animals 
All experiments involving animals were performed according to institutionally 
approved and current animal care guidelines.  Dax1 deficient mice were obtained 
previously (37) and maintained on a 129S1/SvImJ background.  To obtain Dax1
-/y
 mice, 
wild-type males were mated with heterozygous females.  Experimental animals were 
housed with 2-4 animals per cage for up to 100 weeks (n=5 per genotype, per group).  24 
hours before sacrifice, mice were injected with 5-bromo-2-deoxyuridine (BrdU, Roche, 
Basel Germany).  Mice were transferred to single cages and housed in stress-free 
conditions until sacrifice by rapid decapitation at 0800 h.  Trunk blood was collected in 
EDTA-coated collection tubes (Sarstedt).  After decapitation, both adrenal glands, 
pituitaries, and a portion of small intestine were removed and placed in ice cold 
phosphate-buffered saline. 
ACTH Stimulation Test 
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ACTH stimulation test was performed as described previously (45).  Briefly, the 
hypothalamic-pituitary axis was suppressed by injecting 5 g/g body weight 
dexamethasone (Sigma, St. Louis, MO) i.p. at 1800 h one day prior and at 0800 h on the 
day of the assay.  At 1000 h, 1 g/g body weight ACTH 1-24 (Bachem, Torrance, CA) 
was injected i.p. and blood was collected from venous tail puncture at 0, 15, 30, and 60 
minutes post ACTH injection. 
Plasma Hormone Measurements 
Serum ACTH and corticosterone levels were determined by radioimmunoassay 
using a 
125
I RIA kit (MP Biomedicals, Solon, OH) according to the manufacturer‟s 
instructions.  Samples were run in duplicate and quantified using a Gamma Counter. 
Immunohistochemistry 
Tissues were fixed for 2-3 hours in formalin (4% formaldehyde in PBS) and then 
dehydrated in graded ethanol solutions before embedding in paraffin.  Embedded tissues 
were sectioned in 7 m sections and mounted on microscope slides.  Sections were then 
deparaffinized in xylenes (2 X 5 minutes) and rehydrated in graded ethanol.  Antigen 
retrieval was achieved by boiling in Citrate Buffer (10 mM sodium citrate, 0.05% Tween-
20, pH 2.0) for 15 minutes.  Tissue sections were incubated in antibody diluent for 1 hour 
at room temperature and then in primary antibody (custom rabbit anti-Sf1 – 1:2000; rat 
anti-BrdU – 1:500, AdB Serotec; mouse anti-PCNA – 1:1000, Santa Cruz) overnight at 
4°C.  Sections were then incubated with fluorescent dye-conjugated secondary antibody 




Total RNA was isolated from tissues using Trizol Reagent (Invitrogen) and 1 g 
was reverse transcribed using iScript system (BioRad).  The resulting cDNA was diluted 
1:5 and 2 l was amplified with the appropriate primers using SYBR Green PCR Master 
Mix (Applied Biosystems).  Results were analyzed using the 2
-C(T)
 method (46). Primer 
sequences for each amplified gene are: Gapdh: Fwd-5′ aatgtgtccgtcgtggatct, Rev-5′ 
cccagctctccccatcacta; Cyp11b2: Fwd-5′ gcaccaggtggagagtatgc, Rev-5′ 
gccattctggcccatttag; Cyp21a1: Fwd-5′ ctgcttcaccaccctgaga, Rev-5′ agctgcattcggttcctgt, 
Star: Fwd-5′ gctgctcagtattgacctgaag, Rev-5′ gcgataggacctggttgatg; p450scc: For-5′ 
aagtatggccccatttacagg, Rev-5′ tggggtccacgatgtaaact. 
Immunoblotting 
Total cell lysates were prepared in lysis buffer [50 mM Tris-HCl (pH 7.4), 1% 
NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM NaF, and protease 
inhibitor cocktail]. Lysates were allowed to rotate at 4 C for 30 min, and protein contents 
of the high-speed supernatant were measured using the Bradford protein assay (Bio-Rad 
Laboratories, Inc., Hercules, CA). Equivalent quantities of protein (20–45 g) were 
resolved on polyacrylamide-SDS gels, transferred to nitrocellulose membrane (Bio-Rad), 
and immunoblotted with specific antibodies. Results were visualized using the 





Statistical significance was determined by using an unpaired student‟s t-test to 
compare data from Dax1
-/Y
 mice and wild type mice at each age.  Results were 




 mice have altered acute HPA axis responsiveness and baseline HPA axis profile 
To determine if Dax1-deficient mice have an altered steroidogenic profile past 6 
weeks (37), we performed ACTH stimulation tests on 15, 30 and 60 week wild type and 
Dax1
-/Y
 mice.  ACTH stimulation following dexamethasone suppression is a good 
readout of maximal adrenal steroidogenic capacity or responsiveness (45).  15 week 
Dax1
-/Y
 mice have a significantly higher corticosterone output in response to ACTH, 
particularly at the 30 and 60 minute intervals (534 ± 56 vs. 267 ± 81 ng/mL, p < 0.05; 551 
± 50 vs. 322 ± 27 ng/mL, p < 0.05; respectively).  (Figure 3.1 A)  However, 30 week 
Dax1
-/Y
 mice have a similar corticosterone output to wild type mice.  (Figure 3.1 B)  
Notably, 60 week Dax1
-/Y
 mice have significantly reduced ACTH-induced corticosterone 
output at the 60 minute interval (261 ± 63 vs. 540 ± 31 ng/mL, p <0.05. (Figure 3.1 C)   
Based on this initial observation, we next decided to investigate the basal hormonal 
activity of the hypothalamic pituitary axis in Dax1-deficient mice more extensively.  We 
measured plasma hormone levels of wild type and Dax1
-/Y
 mice between 15 and 100 
weeks old and plotted ACTH to corticosterone ratio.   ACTH/corticosterone ratio is an 
ideal method for illustrating actual adrenal steroidogenic responsiveness as a more 
sensitive adrenal will produce a given amount of corticosterone in response to a lower 





have a lower ACTH to corticosterone ratio (3.16 ± 1.02 vs. 8.31 ± 2.05; p < 0.05), 
indicating increased adrenal ACTH sensitivity.   (Figure 3.2)  Mice in the intermediate 
age groups did not have a significant difference in ACTH/corticosterone ratio.  However, 
100 week Dax1
-/Y
 mice had a greater ACTH/corticosterone ratio (10.44 ± 1.61 vs. 4.47 ± 
0.76; p < 0.05; Figure 2), indicating loss of both adrenal steroidogenic sensitivity and 
capacity with age. 
Steroidogenic enzyme gene expression in Dax1
-/Y
 adrenals declines from 15 to 100 weeks 
Differentiation of the adrenal cortex can be analyzed by gene expression of 
relevant enzymes required for steroidogenesis.  To further delineate the changes in 
steroidogenic output of the Dax1-deficient mice, we evaluated gene expression of several 
steroidogenic enzymes at each age by quantitative PCR.  As expected, 15 week Dax1
-/Y
 
mice have elevated adrenal expression of Steroidogenic acute regulatory enzyme (Star) 
mRNA (2.88 ± 0.31 vs. 1.00 ± 0.11 fold, p , 0.05), Side-chain cleavage enzyme (Scc) 
mRNA (6.61 ± 0.88 vs. 1.00 ± 0.09 fold, p < 0.05), and P45011b1 mRNA (3.59 ± 0.41 
vs. 1.00 ± 0.19 fold, p < 0.05) compared to wild-type mice. (Figure 3.3 A)   In 
intermediate ages, expression of steroidogenic enzyme mRNA is not significantly 
different between Dax1
-/Y
 and wild-type mice.  However, 100 week Dax1
-/Y
 mice have 
lower adrenal expression of Star mRNA (0.39 ± 0.02 vs. 1.00 ± 0.16 fold, p < 0.05), Scc 
mRNA (0.36 ± 0.11 vs. 1.00 ± 0.28 fold, p< 0.05), and 11b1 mRNA (0.36 ± 0.02 vs. 1.00 
± 0.24 fold, p < 0.05) compared to wild type mice. 
In order to further confirm the results obtained by qRT-PCR, adrenal protein 
lysates were analyzed by Western blot.  While there was no appreciable change in levels 
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of P450Scc, it is quite striking that StAR protein levels are elevated in the 15- and 30-
week Dax1
-/Y
 adrenals.  However, at 80 weeks, StAR protein levels are dramatically 
lower than its wild-type counterpart.  (Figure 3.3 B) 
Adrenal glands from Dax1-deficient mice display progressively worsening dysplastic 
adrenal morphology 
Because failing adrenals often display abnormal architecture, we compared Dax1 
and wild-type adrenals histologically.  Histological analysis revealed that Dax1
-/Y
 
adrenals have severe morphological abnormalities when compared to wild type adrenals.  
15 weeks Dax1
-/Y
 mice have a somewhat enlarged adrenal cortex, yet maintained normal 
adrenal morphological structure.  (Figure 3.4)  By 55 weeks, adrenals of Dax1
-/Y
 mice 
began to display abnormal architecture.  100 week Dax1
-/Y
 adrenals were severely 
deformed and dysplastic while wild type adrenals maintained normal architecture.  
Additionally, Dax1
-/Y
 adrenals contained large eosinophilic cytomegalic cells. 
Proliferation of Dax1
-/Y
 adrenals declines from 15 to 100 weeks 
To determine if Dax1-deficient mice had altered adrenocortical proliferation, we 
measured BrdU-positive foci by immunohistochemical staining of adrenals with an 
antibody directed against BrdU, and quantified the number of BrdU foci in each adrenal 
and averaged three sections per adrenal.  Adrenals of 15 week Dax1
-/Y
 mice had 
significantly higher levels of BrdU-positive foci than their wild-type counterparts (13.0 ± 
2.5 vs 2.7 ± 0.2; p < 0.05).  30 week Dax1
-/Y
 adrenals had more BrdU-positive foci than 
wild type (6.0 ± 1.0 vs. 2.2 ± 0.2; p < 0.05).  At intermediate ages, the number of BrdU-
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positive foci was not significantly different between the genotypes.  However, 100 week 
Dax1
-/Y
 mice had fewer BrdU-positive foci than their wild-type counterparts (1.9 ± 0.8 vs 
4.1 ± 0.4; p < 0.05).  (Figure 3.5 A)  These results were confirmed by performing 
immunostaining on 15-, 30-, 70-, and 100-week adrenal sections using an antibody 
directed against proliferating cell nuclear antigen (PCNA).  A greater number of cells in 
each adrenal section stained positive for PCNA, but there was an appreciable difference 
between the genotypes.  Adrenals of 15 week Dax1
-/Y
 mice had significantly higher levels 
of PCNA-positive foci than their wild-type counterparts (110.4 ± 27.4 vs 42. ± 3.6; p < 
0.05).  The number of PCNA-positive foci was not significantly different in the 30- and 
60-week adrenals.  However, 100 week Dax1
-/Y
 mice had fewer PCNA-positive foci than 
their wild-type counterparts (9.0 ± 3.8 vs 24.8 ± 3.8; p < 0.05).   (Figure 3.5 B)   
PCNA staining was visualized along with anti-SF1 staining to appreciate the 
differences in young and old mice.  15 week Dax1
-/Y
 adrenals have considerably more 
anti-PCNA staining than wild type, specifically in the subcapsular zone.  Conversely, 100 
week Dax1
-/Y
 adrenals have less anti-PCNA staining than wild-type adrenals, confirming 
that proliferation dramatically decreases in old Dax1
-/Y
 adrenals.  (Figure 3.6)  
Additionally, PCNA protein levels were analyzed by Western blot.  There is appreciably 
more PCNA in 15- and 30-week Dax1 adrenals than in wild-type adrenals.  However, at 





 The primary goal of this study was to reconcile the interspecies variation observed 
in mice and humans deficient in DAX1.  In this study, a similarity in the phenotype of 
Dax1-deficient mice to that of human patients with X-linked AHC is observed.  As 
expected based on earlier studies, young Dax1
-/Y
 mice have enhanced adrenal 
steroidogenesis, which is consistent with the well known repressor function of Dax1in 
steroidogenesis.  However, hormone monitoring and gene expression has demonstrated 
that Dax1
-/Y
 mice have progressively diminishing adrenal steroidogenesis as they age.  
Although young Dax1
-/Y
 mice display enhanced subcapsular proliferation, a progressively 
worsening dysplasia, which is accompanied by a marked decrease in proliferation, is also 
observed with age. 
Symptoms of adrenal failure serve as prompt for sequencing the DAX1 allele, 
leading to diagnosis of X-linked AHC when mutations or deletions are discovered.  
Because hormone monitoring is not standard practice in asymptomatic children, little data 
has been collected on hormone levels of patients with DAX1 mutations prior to 
manifestation of adrenal insufficiency, explaining the paucity of data detailing 
steroidogenic profiles prior to adrenal failure.  However, recent case reports indicate that 
some individuals with DAX1 mutations have elevated cortisol or other steroid hormones 
prior to diagnosis of AHC, which is reversed upon development of the syndrome (9, 19).  
This would reconcile the human data with the mouse data and support a model in which 
loss of Dax1 results in premature differentiation of the adrenal cortex.   
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It is noteworthy that there has been speculation that Dax1
-/Y
 mice might express a 
hypomorphic Dax1 allele, which could explain interspecies phenotype differences (47).  
This speculation is largely due to the method used to generate the knockout – deletion of 
the relatively small exon 2, leaving the larger exon 1 intact.  An alternatively spliced 
isoform, DAX1/DAX1A has been identified in human tissues, consisting of all of exon 
1 and a very short intronic sequence, which would resemble a protein that might be 
produced by the knockout mouse (48, 49).  However, expression of this isoform is 
extremely low compared to the main isoform, raising questions regarding the 
physiological role of DAX1a in steroidogenic tissue development and function (50).  
Additionally, neither a mouse orthologue to DAX1a nor a specific hypomorphic Dax1 in 
the Dax1
-/Y
 mouse has been identified.  Using an antibody that would recognize a 
truncated protein, our lab showed no evidence of truncated protein expression in the 
Dax1
-/Y
 adrenals (37).  Lastly, X-linked AHC still develops in patients with mutations at 
the C-terminus of DAX1 (51).  While the gonadal phenotypes between X-linked AHC 
patients and Dax1
-/Y
 mice are strikingly similar, there are still some noticeable 
differences – mainly that Dax1
-/Y
 mice do not have hypogonadotropic gonadism (36).  In 
all, this may simply reflect heterogeneity and variation along the spectrum of phenotypes 
for DAX1 mutations rather than indicate a hypomorphic allele in the mouse model. 
Recently Dax1 was shown to act as a coactivator when associated with steroid 
receptor RNA activator (SRA) (52).  Interestingly, this interaction occurs at the amino-
terminal region of Dax1, suggesting that it could be preserved in cases where only the 
carboxy-terminus of Dax1 is deleted.  Perhaps Dax1 interaction with SRA provides the 
mechanism by which Dax1 is able to activate genes required for maintenance of 
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adrenocortical progenitor cells.   Interestingly, in light of the fact that his study was 
performed in mouse cells, it is entirely plausible that this interaction is a species-specific 
phenomenon.  Further studies must be performed looking at the SRA in the context of 
Dax1-deficiency as well as the role of SRA in the human adrenal cortex. 
This study is consistent with a role for Dax1 in maintenance of subcapsular  
adrenocortical progenitor cells.  However, Dax1 is clearly not the sole protein that 
functions in such a capacity.  Previous studies have demonstrated that both Wnt-signaling 
and glucocorticoids transcriptionally activate Dax1 (42, 43) and loss of beta-catenin 
results in similar adrenocortical failure and cellular depletion (44, 53).  These data, 
combined with the similar restricted expression of beta-catenin and Dax1 in the 
subcapsular region, lend credence to a physiologic interaction between these pathways in 
maintenance of undifferentiated progenitor cells within the adrenal cortex.  It is, 
therefore, easy to speculate that loss of Dax1 results in premature differentiation of 
adrenocortical progenitor cells, which ultimately leads to adrenal failure.  Loss of a factor 
leading to exhaustion of organ-specific progenitor cells may be fairly common within 
endocrine tissues: human PROP1 mutations result in dramatic variability of pituitary 
morphology and longitudinal imaging revealed pituitary enlargement followed by 
hypoplasia (54, 55).  Data from Prop1-deficient mice, in which a hypoplastic pituitary 
follows expantion of trapped undifferentiated cells, suggests that this may be due to the 
role of Prop1 in migration of progenitor cells into the anterior pituitary (56). 
Cytomegaly is a hallmark phenotype of an adrenal cortex from a patient 
diagnosed with X-linked AHC, though the reason remains unknown (5, 57).  Cytomegaly 
is also a phenotype of other genetic syndromes in which adrenal failure occurs, such as 
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IMAGe Syndrome (58).  Additionally, several mouse models display a similar phenotype 
upon adrenal failure such as the acd mouse that is defective in telomere maintenance (59) 
as well as the adrenal specific beta-catenin knockout  mouse (44).  In the current study, 
adrenal sections of Dax1
-/Y
 mice also display dysmorphic cytomegaly, that increases in 
intensity with age.  It is provocative to speculate that AHC with cytomegaly may 
represent a compensatory morphological endpoint induced by progenitor cell exhaustion.  
Indeed, perhaps the most intriguing phenotype observed in the current study is the 
proliferation difference between Dax1
-/Y
 and wild type mice, particularly at either end of 
the age spectrum.  Young Dax1
-/Y
 mice have a significantly higher proliferation rate (by 
BrdU-positive foci and PCNA staining), while it is dramatically lower in old mice.  This 
is in stark contrast to the relatively constant rate of proliferation seen in the wild type 
mice and to previous assumptions that Dax-deficient adrenals would sacrifice 
proliferation for differentiation (60).  Whether the data reflect loss of direct inhibition by 
Dax1 on subcapsular proliferation or activation or a secondary compensatory mechanism 





Figure 3.1 ACTH stimulation test in 15-, 30-, and 60-week mice. 
ACTH stimulation test was performed by dexamethasone suppression overnight followed 
by injection of ACTH with blood samples collected at 15, 30, and 60 min post-injection.  
Corticosterone was measured by RIA and values were plotted for 15- (A), 30- (B), and 
60-week mice (C). Wild-type are represented by black sqaures, Dax1
-Y
 are represented by 





Figure 3.2 ACTH/Corticosterone ratio at various ages. 
Trunk blood was collected and basal hormone levels were measured using RIA.  The 
level of ACTH was plotted as a ratio to the level of corticosterone for each age. Wild-
type are represented by black bars, Dax1
-Y






Figure 3.3 Gene and protein expression levels at various ages. 
A) mRNA was harvested from fresh adrenals and analyzed by qRT-PCR using primers 
directed against side-chain cleavage enzyme, steroidogenic acute regulatory protein, 
Cyp11b1, and 21-hydroxylase.  Results were plotted relative to wild-type levels, which 
were set to one.  (*, P ≤ 0.05)  B) Protein was isolated from fresh adrenals, run on a 





Figure 3.4 Adrenal histology at various ages. 
Adrenal sections were deparaffinized and stained with Hemtoxylin and Eosin to visualize 
gross changes in histology or morphology.  The two left panels are low magnification and 







Figure 3.5 Proliferation markers at various ages. 
Quantitation of BrdU (A)and PCNA-positive (B) foci per adrenal section.  Foci were 
counted in three adrenal sections for each animal. Results for each age were averaged. 
Wild-type are represented by black bars, Dax1
-Y







Figure 3.6 PCNA immunofluorescence in 15- and 100-week adrenal sections. 
Adrenal sections were probed with antibodies directed against PCNA (green) and SF1 
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SUMMARY AND FUTURE DIRECTIONS 
Summary 
SF1 and DAX1 are nuclear receptors that play an integral role in development and 
function of the adrenal cortex.  SF1 is a transcription factor that strongly activates 
expression of the genes encoding several of the cholesterol transporters and P450 
enzymes required for the conversion of cholesterol into the steroid hormones of the 
adrenal cortex.  Additionally, SF1 regulates the basal expression of several genes, 
including genes involved in steroidogenesis, endocrine signaling, and growth and 
development.  The tissue and temporal specificity of several of these genes demonstrates 
the subtlety with which SF1-dependent transcription is regulated.  It is likely that several 
different signaling pathways regulate SF1-dependent transcription by altering cofactor 
availability or by modulating signaling molecules that impinge on SF1 transactivation.  
These studies describe the regulation by SF1 of several factors that are involved in SF1-
dependent transcription.   
In chapter two, I described the results of a chromatin immunoprecipitation-chip 
microarray (ChIP-chip), in which genomic fragments of SF1 immunoprecipitate were 
analyzed on a promoter microarray.  Promoter regions of a large number of genes were 
enriched.  Surprisingly, there were not a large number of know steroidogenic target 
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genes.  However, of particular interest were enriched targets involved in sphingolipid 
signaling and metabolism, specifically Edg5, which constitutes a novel genomic target of 
SF1-dependent transcription.  Edg5 is the sphingosine 1-phosphate receptor and S1P has 
been shown to stimulate release of steroid hormones from adrenocortical cells.  ACTH 
signaling also increases sphingosine kinase activity, resulting in increased levels of S1P.  
It is interesting to speculate that SF1 increases production of Edg5 to compensate for 
higher levels of intra- and intercellular S1P.  I also described an association of SF1 on the 
Adcy4 promoter.  While in most cases SF1 acts as an activator, on the Adcy4 promoter, 
SF1 acts to repress transcription of Adcy4.  This could possibly be a mechanism by 
which SF1 alters the cellular environment of upstream effectors that result in its 
transcriptional activation.  Finally, I described an interaction between SF1 and GR to 
activate expression of the gene encoding Dax1.  Once again, Dax1 is a factor that alters 
the transcriptional activity of SF1, by inhibiting its transactivation.  In this case, Dax1 is 
fine-tuning the production of glucocorticoids from the adrenal cortex, but this work 
increases the knowledge of what role Dax1 plays in the adrenal cortex.  In all three cases, 
the genomic target of SF1 encodes a factor that can modulate SF1-dependent 
transcription.  This suggests the existence of several mechanisms by which SF1-
dependent transcription is uniquely modulated.   
In chapter 3, I described evidence that Dax1-deficient mice develop adrenal 
failure.  While mutations of DAX1 result in Adrenal Hypoplasia Congenita in humans, 
the Dax1-deficient mouse has a mild adrenal phenotype.  These results potentially 
reconcile the disparity of the phenotypes between the two species.  While the known 
function of DAX1 is to inhibit SF1-dependent transcription, it was, and still remains, 
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puzzling why loss of DAX1 results in adrenal failure.  The Dax1-deficient mouse has 
adrenal hyperfunction, which would be expected based on the ability of Dax1 to inhibit 
SF1.  However, I have shown that Dax1-deficient mice develop adrenal hypofunction late 
in life, suggesting that Dax1 may be maintaining a population of cells in an 
undifferentiated state and that loss of Dax1 results in depletion of this population.  This 
hypothesis is supported by cases of DAX1-deficient patients with elevated hormone 
levels before their adrenals ultimately fail.  In sum, this dissertation contributes to the 
understanding of both SF1-dependent gene regulation and the significance of DAX1 in 
homeostasis of the adult adrenal cortex. 
Future Directions 
 Identifying all of its genomic targets will result in tremendous advancement in the 
understanding of SF1-mediated transcription.  Future studies stemming from the work 
presented here would include fully characterizing the enriched targets of the SF1 ChIP-
chip.  Starting with Edg5, all of the promoters of genes that belong to the sphingolipid 
signaling and metabolism cluster will require further characterization.  This includes 
cloning the full promoter regions and performing luciferase assays to determine the 
context in which these genes are activated.  This can be done under various conditions of 
different hormone treatments or activation of specific signaling pathways.  Finally, the 
SF1 response elements within the promoters would be mutated to determine the 
requirement of SF1 in their transcriptional activation.  Various activators or inhibitors of 
signaling pathways could be used to tease apart the interaction between sphingosine 1-
phosphate signaling and ACTH signaling in adrenocortical cells. 
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 Confirmation of the ChIP-chip data presented in this thesis could be performed 
using newer, more powerful techniques, such as ChIPseq.  Because this method 
sequences all DNA regions that are enriched following chromatin immunoprecipitation, it 
is not limited in scope by genomic region, whereas ChIP-chip will only identify regions 
that are on the particular chip that is being used.  The possibility of identifying 
considerably more targets of SF1 makes this technique an ideal choice for future studies. 
 The fact that SF1 can sometimes act as a repressor of transcription is quite 
intriguing in light of its usual mechanism of action; as an activator of transcription.  Even 
more compelling is the fact the SF1 response element is not different from an element 
that results in activation of target genes.  How then is the protein able to differentiate 
between a gene that is supposed to be activated and one that is to be repressed?  Because 
the sequences are identical, the answer must lie in the sequence surrounding the SF1 
response element.  In the case of Adenylyl cyclase, it seems that specific Sp1 sites result 
in repression of this gene by SF1.  Perhaps this is a unique configuration that always 
results in repression.  Future studies could focus on fully chararterizing sequences 
surrounding SF1 response element in genes that are repressed by SF1.  This would 
provide information regarding the specific transcription factors that, when they interact 
with SF1, result in transcriptional repression.  The ChIP-chip data would prove useful for 
this type of analysis.  Promoters in which ACTH specifically recruits or expels SF1 can 
be aligned and compared for commonalities.  This would provide information regarding 
specific genomic sequences that regulate this type of interaction.   
 The Dax1-deficient mice provide a potentially very useful tool for elucidating the 
function and molecular mechanism of DAX1 in the adrenal cortex.  A personal 
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communication with a collaborator revealed an unpublished case report of a patient with 
late onset AHC that suffered adrenal crisis after a period of extreme physical exertion.  
Perhaps adrenal crisis could be forced in Dax1
-/Y
 mice by prolonged exposure to ACTH.  
A simple experiment would be to activate the HPA axis in the Dax1
-/Y
 mice to observe 
signs of premature failure compared to the wild-type mice.  This could be accomplished 
by giving daily ACTH injections for a period of time or by fasting, which induces the 
HPA axis.  However, if longer periods of HPA axis activation are needed, a pellet could 
be implanted under the skin.  If Dax1 mice demonstrated adrenal failure earlier than wild-
type mice, it would be consistent with Dax1 maintaining the undifferentiated state of the 
adrenal cortex.  This will provide greater insight regarding the function of DAX1 in 
maintaining the adult adrenal cortex and would further reconcile human and mouse 
DAX1 deficiencies. 
 The contribution of Dax1 to the adult adrenal cortex would probably best be 
modeled using system in which Dax1 is genetically inactivated after the adrenal has 
already formed.  By crossing floxed Dax1 mice with mice that express a tetracycline-
inducible cre recombinase, Dax1 could be inactivated at any age.  Many of the 
experiment performed in chapter 3 of this thesis could be performed in this genetic 
context as well.  Ideally, lineage tracing would be employed so that cells in which Dax1 
was deleted could be traced throughout the adrenal.  I would predict that this scenario 
would reveal cells continuously populating the adrenal cortex after the deletion of Dax1.  
The strength of this type of assay is the ability to observe Dax1-ablated adrenals at any 
point after inducing the cre recombinase.  Presumably, cells in which Dax1 had been 
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recently deleted would be found close to the capsule, while cells in which Dax1 had been 
deleted for a longer period of time would be observed within the adrenal cortex.   
 Finally, the Dax1-deficient mouse could be used in developmental studies.  
Because it was previously shown the Dax1 specifically inhibits expression of FAdE, 
breeding the Dax1
+/- 
mouse with the FAdE reporter mouse could provide compelling 
results.  In this cross FAdE could be traced in the context of Dax1 deficiency.  Because, 
Dax1 normally represses FAdE in the developing adrenal cortex, it might be predicted 
that FAdE expression would persist into the adult adrenal.  It would be interesting to 
determine if the adult adrenal forms properly, or if the fetal adrenal persists, but then 
eventually fails.  All together the Dax1-deficient mice will provide a useful tool for 
understanding the complexities of the development and maintenance of the adrenal 
cortex.  
 To fully understand the molecular mechanism of Dax1 action in the adrenal 
cortex, the full complement of genomic targets must be elucidated.  While it is know that 
Dax1 inhibits SF1-dependent transcription, this mechanism is insufficient to explain how 
Dax1 maintains undifferentiated adrenocortical cells.  It is highly likely that Dax1 is 
inhibiting other transcription factors as well.  Future studies could make use of genomic 
profiling techniques, such as ChIP-chip and ChIPseq to determine the genomic targets of 
Dax1 in the subcapsular cells of the adrenal cortex.  Additionally, techniques such as 
tandem affinity purification could be used to define the proteins with which Dax1 
interacts.  I believe that these types of studies will be used to further define the role of 
Dax1 in the adrenal cortex and put it in its rightful place at the forefront of adrenal 
biology.   
